Jennifer Keating Litton, M.D., MHCM

Peer-Reviewed Articles

1. Leonard L, Yi M, Wingate E, Singh P, Caudle A, Hwang RF, Bedrosian I, Valero V, Litton J, Ibrahim N, Hunt KK. Axillary Management after Neoadjuvant Endocrine Therapy (NET). Ann Surg Oncol, 2025. e-Pub 2025. PMID: 41455847.
2. Guirguis MS, Adrada BE, Yam C, Tripathy D, Candelaria R, Yang W, Patel M, Moseley T, Perez F, Whitman GJ, Leung JWT, Le-Petross H, Lane DL, Huo L, Litton JK, Valero V, Hunt KK, Arun B, Mohamed R, Sun J, Korkut A, Xu Z, Pashapoor S, White J, Son JB, Thompson A, Wei P, Ma J, Moulder S, Rauch GM. Early tumor volume reduction by breast DCE MRI predicts pathologic complete response to neoadjuvant therapy in triple negative breast cancer. NPJ Breast Cancer 11(1):129, 2025. e-Pub 2025. PMID: 41266347.
3. Chen, JH, Warneke, C, Middleton, LP, Singh, P, Kuerer, HM, Hunt, KK, Martinez, A, Litton, J, Oke, OC, Johnson, HM. Complication Rates are Low After Invasive Procedures on the Lactating Breast in Patients Treated for Breast Cancer During Pregnancy. Annals of surgical oncology 32(11):8196-8206, 2025. e-Pub 2025. PMID: 40676422.
4. Adrada BE, Guirguis MS, Huo L, Yam C, Tripathy D, Candelaria R, Yang W, Patel M, Moseley T, Whitman GJ, Leung JWT, Le-Petross H, Lane DL, Abuhadra N, Litton J, Valero V, Hunt KK, Arun B, Mohamed R, Sun J, Korkut A, Pashapoor S, White J, Thompson A, Wei P, Ma J, Moulder S, Rauch GM. Imaging- and Tumor Biomarker-Based Multivariable Model for Early Prediction of Pathologic Complete Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer. JCO Precis Oncol 9:e2500410, 2025. e-Pub 2025. PMID: 41411609.
5. Chen MK, Yamaguchi H, Gao Y, Xia W, Chang JT, Hsiao YC, Shegute TW, Lin ZS, Wu CS, Wang YH, Litton JK, Ding Q, Wei Y, Chu YY, Meric-Bernstam F, Piwnica-Worms H, Arun B, Rodon Ahnert J, Liu J, Yao J, Chang WC, Wang HL, Tapia C, Albarracin CT, Keyomarsi K, Wang SC, Wang YN, Hortobagyi GN, Lin C, Yang L, Yu D, Hung MC. FGFR3-induced Y158 PARP1 phosphorylation promotes PARP inhibitor resistance via BRG1/MRE11-mediated DNA repair in breast cancer models. J Clin Invest 135(14), 2025. e-Pub 2025. PMID: 40460005.
6. Wanis KN, Mitchell MP, Giordano SH, Litton JK, Shaitelman SF, Tamirisa N, Bedrosian I, Dong W, Shen Y, Hunt KK, Singh P, Sun SX, Caudle AS, Kuerer HM, Meric-Bernstam F, Hwang RF, Adesoye T. Implications of omitting sentinel lymph node biopsy on adjuvant decision making for patients with small breast cancers. Cancer 131(11):e35910, 2025. e-Pub 2025. PMID: 40433858.
7. Schalck A, Tran T, Li J, Sei E, Bai S, Hu M, Lin J, Bright SJ, Reddick S, Yang F, Batra H, Contreras A, Raso MG, Stauder MC, Hoffman KE, Reddy JP, Nead KT, Smith BD, Sawakuchi GO, Woodward WA, Watowich SS, Litton JK, Bedrosian I, Mittendorf EA, Le-Petross H, Navin NE, Shaitelman SF. The impact of breast radiotherapy on the tumor genome and immune ecosystem. Cell Rep 44(5):115703, 2025. e-Pub 2025. PMID: 40378044.
8. Xu, Z, Zhou, Z, Son, JB, Feng, H, Adrada, BE, Moseley, T, Candelaria, RP, Guirguis, MS, Patel, MM, Whitman, GJ, Leung, J, Le-Petross, H, Mohamed, R, Panthi, B, Lane, DL, Chen, H, Wei, P, Tripathy, D, Litton, J, Valero, V, Huo, L, Hunt, KK, Korkut, A, Thompson, A, Yang, W, Yam, C, Rauch, GM, Ma, J. Deep Learning Models Based on Pretreatment MRI and Clinicopathological Data to Predict Responses to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer. Cancers 17(6), 2025. e-Pub 2025. PMID: 40149299.
9. Shaitelman SF, Le-Petross H, Raso MG, Swanson DM, Schalck AP, Contreras A, Yang F, Muruganandham M, Zhao GZ, Sawakuchi GO, Kim LH, Batra H, Smith BD, Stauder MC, Woodward WA, Reddy JP, Litton JK, Thompson A, Bedrosian I, Mittendorf EA. PRECISE: Preoperative Radiation Therapy to Elicit Critical Immune Stimulating Effects-A Phase 2 Clinical Trial. Int J Radiat Oncol Biol Phys 121(1):90-96, 2025. e-Pub 2025. PMID: 39147206.
10. Faiz SA, Knox AS, Fellman B, Jaumally BA, Pacheco GN, Das A, Mathew R, Murthy R, Litton JK, Balachandran DD, Bashoura L. Sleep disturbances based on patient reported outcomes in patients with breast cancer. Sleep Breath 28(6):2491-2500, 2024. e-Pub 2024. PMID: 39225722.
11. Johnson HM, Song J, Warneke CL, Martinez AL, Litton JK, Oke OC. Outcomes of patients treated with chemotherapy for breast cancer during pregnancy compared with nonpregnant breast cancer patients treated with systemic therapy. Cancer 131(1), 2024. e-Pub 2024. PMID: 39470464.
12. Yam C, Patel M, Hill HA, Sun R, Bassett RL Jr, Kong E, Damodaran S, Koenig KB, Abouharb S, Saleem S, Bisen AK, Murthy RK, Ramirez DL, Rauch GM, Adrada BE, Candelaria RP, Wang X, Mittendorf EA, Thompson AM, White JB, Ravenberg EE, Clayborn AR, Ding QQ, Booser DJ, Oke O, Brewster AM, Hortobagyi GN, Ibrahim NK, Litton JK, Valero V, Arun BK, Tripathy D, Chang JT, Chen K, Korkut A, Moulder SL, Huo L, Lim B, Ueno NT. Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study. Cancer Res Commun 4(10):2823-2834, 2024. e-Pub 2024. PMID: 39356138.
13. Lin LL, Wong F, Lin R, Yap T, Litton JK. Pharmacodynamic Activity of [(18)F]-Fluorthanatrace Poly(ADP-ribose) Polymerase Positron Emission Tomography in Patients With BRCA1/2-Mutated Breast Cancer Receiving Talazoparib. JCO Precis Oncol 8:e2400303, 2024. e-Pub 2024. PMID: 39208372.
14. Mohamed RM, Panthi B, Adrada BE, Boge M, Candelaria RP, Chen H, Guirguis MS, Hunt KK, Huo L, Hwang KP, Korkut A, Litton JK, Moseley TW, Pashapoor S, Patel MM, Reed B, Scoggins ME, Son JB, Thompson A, Tripathy D, Valero V, Wei P, White J, Whitman GJ, Xu Z, Yang W, Yam C, Ma J, Rauch GM. Multiparametric MRI-based radiomic models for early prediction of response to neoadjuvant systemic therapy in triple-negative breast cancer. Sci Rep 14(1):16073, 2024. e-Pub 2024. PMID: 38992094.
15. Lim B, Seth S, Yam C, Huo L, Fujii T, Lee J, Bassett R, Nasser S, Ravenberg L, White J, Clayborn A, Guerra G, Litton JK, Damodaran S, Layman R, Valero V, Tripathy D, Lewis M, Dobrolecki LE, Lei J, Candelaria R, Arun B, Rauch G, Zhao L, Zhang J, Ding Q, Symmans WF, Chang JT, Thompson AM, Moulder SL, Ueno NT. Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into "ARness". Cell Rep Med 5(6):101595, 2024. e-Pub 2024. PMID: 38838676.
16. Telli ML, Litton JK, Beck JT, Jones JM, Andersen J, Mina LA, Brig R, Danso M, Yuan Y, Symmans WF, Hopkins JF, Albacker LA, Abbattista A, Noonan K, Mata M, Laird AD, Blum JL. Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status. Breast Cancer 31(5):886-897, 2024. e-Pub 2024. PMID: 38869771.
17. Garber HR, Basu S, Jindal S, He Z, Chu K, Raghavendra AS, Yam C, Santiago L, Adrada BE, Sharma P, Mittendorf EA, Litton JK. Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II-III breast cancer. Oncotarget 15:238-247, 2024. e-Pub 2024. PMID: 38502947.
18. Basho RK, Zhao L, White JB, Huo L, Bassett RL, Mittendorf EA, Thompson A, Litton JK, Ueno N, Arun B, Lim B, Valero V, Tripathy D, Zhang J, Adrada BE, Santiago L, Ravenberg E, Seth S, Yam C, Moulder SL, Damodaran S. Comprehensive Analysis Identifies Variability in PI3K Pathway Alterations in Triple-Negative Breast Cancer Subtypes. JCO Precis Oncol 8:e2300124, 2024. e-Pub 2024. PMID: 38484209.
19. Musall BC, Rauch DE, Mohamed RMM, Panthi B, Boge M, Candelaria RP, Chen H, Guirguis MS, Hunt KK, Huo L, Hwang KP, Korkut A, Litton JK, Moseley TW, Pashapoor S, Patel MM, Reed BJ, Scoggins ME, Son JB, Tripathy D, Valero V, Wei P, White JB, Whitman GJ, Xu Z, Yang WT, Yam C, Adrada BE, Ma J. Diffusion Tensor Imaging for Characterizing Changes in Triple-Negative Breast Cancer During Neoadjuvant Systemic Therapy. J Magn Reson Imaging 60(4):1367-1376, 2024. e-Pub 2024. PMID: 38294179.
20. Xu Z, Rauch DE, Mohamed RM, Pashapoor S, Zhou Z, Panthi B, Son JB, Hwang KP, Musall BC, Adrada BE, Candelaria RP, Leung JWT, Le-Petross HTC, Lane DL, Perez F, White J, Clayborn A, Reed B, Chen H, Sun J, Wei P, Thompson A, Korkut A, Huo L, Hunt KK, Litton JK, Valero V, Tripathy D, Yang W, Yam C, Ma J. Deep Learning for Fully Automatic Tumor Segmentation on Serially Acquired Dynamic Contrast-Enhanced MRI Images of Triple-Negative Breast Cancer. Cancers (Basel) 15(19), 2023. e-Pub 2023. PMID: 37835523.
21. Akkoc Mustafayev FN, Liu DD, Gutierrez AM, Lewis JE, Ibrahim NK, Valero V, Booser DJ, Litton JK, Koenig K, Yu D, Sneige N, Arun BK. Short-Term Biomarker Modulation Study of Dasatinib for Estrogen Receptor-Negative Breast Cancer Chemoprevention. Eur J Breast Health 19(4):267-273, 2023. e-Pub 2023. PMID: 37795002.
22. Panthi B, Mohamed RM, Adrada BE, Boge M, Candelaria RP, Chen H, Hunt KK, Huo L, Hwang KP, Korkut A, Lane DL, Le-Petross HC, Leung JWT, Litton JK, Pashapoor S, Perez F, Son JB, Sun J, Thompson A, Tripathy D, Valero V, Wei P, White J, Xu Z, Yang W, Zhou Z, Yam C, Rauch GM, Ma J. Longitudinal dynamic contrast-enhanced MRI radiomic models for early prediction of response to neoadjuvant systemic therapy in triple-negative breast cancer. Front Oncol 13:1264259, 2023. e-Pub 2023. PMID: 37941561.
23. Noh, S, Bertini, CD, Mira-Avendano, I, Kaous, M, Patel, B, Faiz, S, Shannon, VR, Balachandran, D, Bashoura, L, Adachi, R, Evans, S, Dickey, BF, Wu, CC, Shroff, G, Manzano, JM, Granwehr, BP, Holloway, S, Dickson, KB, Mohammed, AD, Muthu, M, Song, H, Aroe, A, Aloia, TA, Lee Andrews, II, Badami, KK, Beird, H, Brock, K, Cata, JP, Dabaja, BS, Draetta, G, French, KE, Godoy, M, Hutcheson, KA, Jaffray, D, John, TM, Lee, JJ, Litton, J, McEnery, KW, Musunuru, TN, Nates, JL, Palaskas, NL, Ravi, V, Scheet, PA, Shete, S, Subbiah, IM, Tawbi, H, Woodman, SE, Chung, C, Khawaja, F, Sheshadri, A. Interstitial lung abnormalities after hospitalization for COVID-19 in patients with cancer. Cancer medicine 12(17):17753-17765, 2023. e-Pub 2023. PMID: 37592894.
24. Litton JK, Regan MM, Pusztai L, Rugo HS, Tolaney SM, Garrett-Mayer E, Amiri-Kordestani L, Basho RK, Best AF, Boileau JF, Denkert C, Foster JC, Harbeck N, Jacene HA, King TA, Mason G, O'Sullivan CC, Prowell TM, Richardson AL, Sepulveda KA, Smith ML, Tjoe JA, Turashvili G, Woodward WA, Butler LP, Schwartz EI, Korde LA. Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP. J Clin Oncol 41(27):JCO2300435, 2023. e-Pub 2023. PMID: 37433103.
25. Chen H, Ding Q, Khazai L, Zhao L, Damodaran S, Litton JK, Rauch GM, Yam C, Chang JT, Seth S, Lim B, Thompson AM, Mittendorf EA, Adrada B, Virani K, White JB, Ravenberg E, Song X, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Routbort MJ, Sahin A, Valero V, Symmans WF, Tripathy D, Wang WL, Moulder S, Huo L. PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimens. Ther Adv Med Oncol 15:17588359231189422, 2023. e-Pub 2023. PMID: 37547448.
26. Zhou, Z, Adrada, BE, Candelaria, RP, Elshafeey, N, Boge, M, Mohamed, RM, Pashapoor, S, Sun, J, Xu, Z, Panthi, B, Son, JB, Guirguis, MS, Patel, MM, Whitman, GJ, Moseley, T, Scoggins, ME, White, JB, Litton, J, Valero, V, Hunt, KK, Tripathy, D, Yang, W, Wei, P, Yam, C, Pagel, MD, Rauch, GM, Ma, J. Predicting pathological complete response to neoadjuvant systemic therapy for triple-negative breast cancers using deep learning on multiparametric MRIs. Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference 2023:1-4, 2023. e-Pub 2023. PMID: 38083160.
27. Hwang KP, Elshafeey NA, Kotrotsou A, Chen H, Son JB, Boge M, Mohamed RM, Abdelhafez AH, Adrada BE, Panthi B, Sun J, Musall BC, Zhang S, Candelaria RP, White JB, Ravenberg EE, Tripathy D, Yam C, Litton JK, Huo L, Thompson AM, Wei P, Yang WT, Pagel MD, Ma J, Rauch GM. A Radiomics Model Based on Synthetic MRI Acquisition for Predicting Neoadjuvant Systemic Treatment Response in Triple-Negative Breast Cancer. Radiol Imaging Cancer 5(4):e230009, 2023. e-Pub 2023. PMID: 37505106.
28. Yam C, Mittendorf EA, Garber HR, Sun R, Damodaran S, Murthy RK, Ramirez D, Karuturi M, Layman RM, Ibrahim N, Rauch GM, Adrada BE, Candelaria RP, White JB, Ravenberg E, Clayborn A, Ding QQ, Symmans WF, Prabhakaran S, Thompson AM, Valero V, Tripathy D, Huo L, Moulder SL, Litton JK. A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer. Breast Cancer Res Treat 199(3):457-469, 2023. e-Pub 2023. PMID: 37061619.
29. Abuhadra N, Sun R, Yam C, Rauch GM, Ding Q, Lim B, Thompson AM, Mittendorf EA, Adrada BE, Damodaran S, Virani K, White J, Ravenberg E, Sun J, Choi J, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Sahin A, Valero V, Symmans WF, Litton JK, Tripathy D, Moulder S, Huo L. Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial. Cancers (Basel) 15(13), 2023. e-Pub 2023. PMID: 37444385.
30. Litton JK, Beck JT, Jones JM, Andersen J, Blum JL, Mina LA, Brig R, Danso M, Yuan Y, Abbattista A, Noonan K, Niyazov A, Chakrabarti J, Czibere A, Symmans WF, Telli ML. Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study. Oncologist 28(10):845-855, 2023. e-Pub 2023. PMID: 37318349.
31. Abuhadra N, Sun R, Bassett RL, Huo L, Chang JT, Teshome M, Clayborn AR, White JB, Ravenberg EE, Adrada BE, Candelaria RP, Yang W, Ding Q, Symmans WF, Arun B, Damodaran S, Koenig KB, Layman RM, Lim B, Litton JK, Thompson A, Ueno NT, Piwnica-Worms H, Hortobagyi GN, Valero V, Tripathy D, Rauch GM, Moulder S, Yam C. Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy. Invest New Drugs 41(3):391-401, 2023. e-Pub 2023. PMID: 37043123.
32. Reddy, DS, Cuenca, JA, Botdorf, JS, Muthu, M, Hanmandlu, A, Wegner, RC, Crommett, JW, Gutierrez, C, Rathi, N, Sajith, B, Knafl, M, Abbas, HA, Woodman, SE, Nates, JL, Aaroe, AE, Aloia, TA, Andrews, L, Badami, KK, Baganz, JA, Bajwa, P, Baker, LR, Barbosa, GR, Beird, H, Bourgeois, M, Brock, K, Burton, EM, Cata, JP, Chung, C, Cutherell, M, Dabaja, BS, Draetta, G, French, KE, Futreal, A, Gibbons, C, Godoy, M, Gunther, J, Hutcheson, KA, Jaffray, D, John, TM, Lee, JJ, Litton, J, McEnery, KW, Palaskas, NL, Ravi, V, Scheet, PA, Schmidt, S, Subbiah, IM, Tawbi, H, Wu, J, Yao, JC. Clinical Characteristics and Cause of Death Among Hospitalized Decedents With Cancer and COVID-19. Mayo Clinic Proceedings 98(3):451-457, 2023. e-Pub 2023. PMID: 36868753.
33. Postel-Vinay S, Lam VK, Ros W, Bauer TM, Hansen AR, Cho DC, Stephen Hodi F, Schellens JHM, Litton JK, Aspeslagh S, Autio KA, Opdam FL, McKean M, Somaiah N, Champiat S, Altan M, Spreafico A, Rahma O, Paul EM, Ahlers CM, Zhou H, Struemper H, Gorman SA, Watmuff M, Yablonski KM, Yanamandra N, Chisamore MJ, Schmidt EV, Hoos A, Marabelle A, Weber JS, Heymach JV. First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1). J Immunother Cancer 11(3), 2023. e-Pub 2023. PMID: 36927527.
34. Panthi B, Adrada BE, Candelaria RP, Guirguis MS, Yam C, Boge M, Chen H, Hunt KK, Huo L, Hwang KP, Korkut A, Lane DL, Le-Petross HC, Leung JWT, Litton JK, Mohamed RM, Musall BC, Pashapoor S, Patel MM, Perez F, Son JB, Thompson A, Valero V, Wei P, White J, Xu Z, Pinsky L, Tripathy D, Yang W, Ma J, Rauch GM. Assessment of Response to Neoadjuvant Systemic Treatment in Triple-Negative Breast Cancer Using Functional Tumor Volumes from Longitudinal Dynamic Contrast-Enhanced MRI. Cancers (Basel) 15(4), 2023. e-Pub 2023. PMID: 36831368.
35. Zhou Z, Adrada BE, Candelaria RP, Elshafeey NA, Boge M, Mohamed RM, Pashapoor S, Sun J, Xu Z, Panthi B, Son JB, Guirguis MS, Patel MM, Whitman GJ, Moseley TW, Scoggins ME, White JB, Litton JK, Valero V, Hunt KK, Tripathy D, Yang W, Wei P, Yam C, Pagel MD, Rauch GM, Ma J. Prediction of pathologic complete response to neoadjuvant systemic therapy in triple negative breast cancer using deep learning on multiparametric MRI. Sci Rep 13(1):1171, 2023. e-Pub 2023. PMID: 36670144.
36. Musall BC, Adrada BE, Candelaria RP, Mohamed RMM, Abdelhafez AH, Son JB, Sun J, Santiago L, Whitman GJ, Moseley TW, Scoggins ME, Mahmoud HS, White JB, Hwang KP, Elshafeey NA, Boge M, Zhang S, Litton JK, Valero V, Tripathy D, Thompson AM, Yam C, Wei P, Moulder SL, Pagel MD, Yang WT, Ma J, Rauch GM. Quantitative Apparent Diffusion Coefficients From Peritumoral Regions as Early Predictors of Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer. J Magn Reson Imaging 56(6):1901-1909, 2022. e-Pub 2022. PMID: 35499264.
37. Kumar T, Hobbs E, Yang F, Chang JT, Contreras A, Cuentas ERP, Garber H, Lee S, Lu Y, Scoggins ME, Adrada BE, Whitman GJ, Arun BK, Mittendorf EA, Litton JK. Tumor immune microenvironment changes by multiplex immunofluorescence staining in a pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a hereditary BRCA mutation. Clin Cancer Res 28(17):3669-3676, 2022. e-Pub 2022. PMID: 35736816.
38. Wu C, Jarrett AM, Zhou Z, Elshafeey N, Adrada BE, Candelaria RP, Mohamed RMM, Boge M, Huo L, White JB, Tripathy D, Valero V, Litton JK, Yam C, Son JB, Ma J, Rauch GM, Yankeelov TE. MRI-based digital models forecast patient-specific treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer. Cancer Res 82(18):3394-3404, 2022. e-Pub 2022. PMID: 35914239.
39. Irajizad E, Wu R, Vykoukal J, Murage E, Spencer R, Dennison JB, Moulder S, Ravenberg E, Lim B, Litton J, Tripathym D, Valero V, Damodaran S, Rauch GM, Adrada B, Candelaria R, White JB, Brewster A, Arun B, Long JP, Do KA, Hanash S, Fahrmann JF. Application of Artificial Intelligence to Plasma Metabolomics Profiles to Predict Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. Front Artif Intell 5:876100, 2022. e-Pub 2022. PMID: 36034598.
40. Yam C, Abuhadra N, Sun R, Adrada BE, Ding QQ, White JB, Ravenberg EE, Clayborn AR, Valero V, Tripathy D, Damodaran S, Arun BK, Litton JK, Ueno NT, Murthy RK, Lim B, Baez L, Li X, Buzdar AU, Hortobagyi GN, Thompson AM, Mittendorf EA, Rauch GM, Candelaria RP, Huo L, Moulder SL, Chang JT. Molecular characterization and prospective evaluation of pathological response and outcomes with neoadjuvant therapy in metaplastic triple-negative breast cancer. Clin Cancer Res 28(13):2878-2889, 2022. e-Pub 2022. PMID: 35507014.
41. Sun X, Zhai J, Sun B, Parra ER, Jiang M, Ma W, Wang J, Kang AM, Kannan K, Pandurengan R, Zhang S, Solis LM, Haymaker CL, Raso MG, Mendoza Perez J, Sahin AA, Wistuba II, Yam C, Litton JK, Yang F. Effector memory cytotoxic CD3+/CD8+/CD45RO+ T cells are predictive of good survival and a lower risk of recurrence in triple-negative breast cancer. Mod Pathol 35(5):601-608, 2022. e-Pub 2022. PMID: 34839351.
42. Liu X, Ge Z, Yang F, Contreras A, Lee S, White JB, Lu Y, Labrie M, Arun BK, Moulder SL, Mills GB, Piwnica-Worms H, Litton JK, Chang JT. Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers. NPJ Breast Cancer 8(1):64, 2022. e-Pub 2022. PMID: 35538088.
43. Blum JL, Laird AD, Litton JK, Rugo HS, Ettl J, Hurvitz SA, Martin M, Roché HH, Lee KH, Goodwin A, Chen Y, Lanzalone S, Chelliserry J, Czibere A, Hopkins JF, Albacker LA, Mina LA. Determinants of Response to Talazoparib in Patients with HER2-negative, Germline BRCA1/2-mutated Breast Cancer. Clin Cancer Res 28(7):1383-1390, 2022. e-Pub 2022. PMID: 35091441.
44. Jimenez JE, Abdelhafez A, Mittendorf EA, Elshafeey N, Yung JP, Litton JK, Adrada BE, Candelaria RP, White J, Thompson AM, Huo L, Wei P, Tripathy D, Valero V, Yam C, Hazle JD, Moulder SL, Yang WT, Rauch GM. A model combining pretreatment MRI radiomic features and tumor-infiltrating lymphocytes to predict response to neoadjuvant systemic therapy in triple-negative breast cancer. Eur J Radiol 149:110220, 2022. e-Pub 2022. PMID: 35193025.
45. Abuhadra N, Sun R, Litton JK, Rauch GM, Yam C, Chang JT, Seth S, Bassett R, Lim B, Thompson AM, Mittendorf E, Adrada BE, Damodaran S, White J, Ravenberg E, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Sahin AA, Valero V, Symmans WF, Tripathy D, Moulder S, Huo L. Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer. Cancers (Basel) 14(5), 2022. e-Pub 2022. PMID: 35267631.
46. Chapman BV, Liu D, Shen Y, Olamigoke OO, Lakomy DS, Barrera AMG, Stecklein SR, Sawakuchi GO, Bright SJ, Bedrosian I, Litton JK, Smith BD, Woodward WA, Perkins GH, Hoffman KE, Stauder MC, Strom EA, Arun BK, Shaitelman SF. Outcomes After Breast Radiation Therapy in a Diverse Patient Cohort With a Germline BRCA1/2 Mutation. Int J Radiat Oncol Biol Phys 112(2):426-436, 2022. e-Pub 2022. PMID: 34610390.
47. Chapman BV, Liu D, Shen Y, Olamigoke OO, Lakomy DS, Barrera AMG, Stecklein SR, Sawakuchi GO, Bright SJ, Bedrosian I, Litton JK, Smith BD, Woodward WA, Perkins GH, Hoffman KE, Stauder MC, Strom EA, Arun BK, Shaitelman SF. Breast Radiation Therapy-Related Treatment Outcomes in Patients With or Without Germline Mutations on Multigene Panel Testing. Int J Radiat Oncol Biol Phys 112(2):437-444, 2022. e-Pub 2022. PMID: 34582940.
48. Candelaria RP, Spak DA, Rauch GM, Huo L, Bassett RL, Santiago L, Scoggins ME, Guirguis MS, Patel MM, Whitman GJ, Moulder SL, Thompson AM, Ravenberg EE, White JB, Abuhadra NK, Valero V, Litton J, Adrada BE, Yang WT. BI-RADS Ultrasound Lexicon Descriptors and Stromal Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. Acad Radiol 29 Suppl 1(Suppl 1):S35-S41, 2022. e-Pub 2022. PMID: 34272161.
49. Burstein HJ, Somerfield MR, Barton DL, Dorris A, Fallowfield LJ, Jain D, Johnston SRD, Korde LA, Litton JK, Macrae ER, Peterson LL, Vikas P, Yung RL, Rugo HS. Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update. J Clin Oncol 39(35):JCO2101392, 2021. e-Pub 2021. PMID: 34324367.
50. Westin SN, Labrie M, Litton JK, Blucher A, Fang Y, Vellano CP, Marszalek JR, Feng N, Ma X, Creason A, Fellman B, Yuan Y, Lee S, Kim TB, Liu J, Chelariu-Raicu A, Chen TH, Kabil N, Soliman PT, Frumovitz M, Schmeler KM, Jazaeri A, Lu KH, Murthy R, Meyer LA, Sun CC, Sood AK, Coleman RL, Mills GB. Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. Clin Cancer Res 27(23):6354-6365, 2021. e-Pub 2021. PMID: 34518313.
51. Kai M, Marx AN, Liu DD, Shen Y, Gao H, Reuben JM, Whitman G, Krishnamurthy S, Ross MI, Litton JK, Lim B, Ibrahim N, Kogawa T, Ueno NT. A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer. Sci Rep 11(1):22242, 2021. e-Pub 2021. PMID: 34782633.
52. Hobbs EA, Litton JK, Yap TA. Development of the PARP inhibitor talazoparib for the treatment of advanced BRCA1 and BRCA2 mutated breast cancer. Expert Opin Pharmacother 22(14):1-13, 2021. e-Pub 2021. PMID: 34309473.
53. Adrada BE, Candelaria R, Moulder S, Thompson A, Wei P, Whitman GJ, Valero V, Litton JK, Santiago L, Scoggins ME, Moseley TW, White JB, Ravenberg EE, Yang WT, Rauch GM. Early ultrasound evaluation identifies excellent responders to neoadjuvant systemic therapy among patients with triple-negative breast cancer. Cancer 127(16):2880-2887, 2021. e-Pub 2021. PMID: 33878210.
54. Emens LA, Adams S, Cimino-Mathews A, Disis ML, Gatti-Mays ME, Ho AY, Kalinsky K, McArthur HL, Mittendorf EA, Nanda R, Page DB, Rugo HS, Rubin KM, Soliman H, Spears PA, Tolaney SM, Litton JK. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. J Immunother Cancer 9(8), 2021. e-Pub 2021. PMID: 34389617.
55. Musall BC, Abdelhafez AH, Adrada BE, Candelaria RP, Mohamed RMM, Boge M, Le-Petross H, Arribas E, Lane DL, Spak DA, Leung JWT, Hwang KP, Son JB, Elshafeey NA, Mahmoud HS, Wei P, Sun J, Zhang S, White JB, Ravenberg EE, Litton JK, Damodaran S, Thompson AM, Moulder SL, Yang WT, Pagel MD, Rauch GM, Ma J. Functional Tumor Volume by Fast Dynamic Contrast-Enhanced MRI for Predicting Neoadjuvant Systemic Therapy Response in Triple-Negative Breast Cancer. J Magn Reson Imaging 54(1):251-260, 2021. e-Pub 2021. PMID: 33586845.
56. Yam C, Yen EY, Chang JT, Bassett RL, Alatrash G, Garber H, Huo L, Yang F, Philips AV, Ding QQ, Lim B, Ueno NT, Kannan K, Sun X, Sun B, Parra Cuentas ER, Symmans WF, White JB, Ravenberg E, Seth S, Guerriero JL, Rauch GM, Damodaran S, Litton JK, Wargo JA, Hortobagyi GN, Futreal A, Wistuba II, Sun R, Moulder SL, Mittendorf EA. Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer. Clin Cancer Res 27(19):5365-5375, 2021. e-Pub 2021. PMID: 34253579.
57. McGrail DJ, Pilié PG, Rashid NU, Voorwerk L, Slagter M, Kok M, Jonasch E, Khasraw M, Heimberger AB, Lim B, Ueno NT, Litton JK, Ferrarotto R, Chang JT, Moulder SL, Lin SY. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol 32(5):661-672, 2021. e-Pub 2021. PMID: 33736924.
58. Chick RC, Clifton GT, Hale DF, Vreeland TJ, Hickerson AT, Kemp Bohan PM, McCarthy PM, Litton JK, Alatrash G, Murthy RK, Qiao N, Philips A, Lukas J, Holmes JP, Mittendorf EA, Peoples GE. Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer. Clin Immunol 225:108679, 2021. e-Pub 2021. PMID: 33485895.
59. Yam C, Rauch GM, Rahman T, Karuturi M, Ravenberg E, White J, Clayborn A, McCarthy P, Abouharb S, Lim B, Litton JK, Ramirez DL, Saleem S, Stec J, Symmans WF, Huo L, Damodaran S, Sun R, Moulder SL. A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer. Invest New Drugs 39(2):509-515, 2021. e-Pub 2021. PMID: 32984932.
60. Daly MB, Pal T, Berry MP, Buys SS, Dickson P, Domchek SM, Elkhanany A, Friedman S, Goggins M, Hutton ML, CGC, Karlan BY, Khan S, Klein C, Kohlmann W, CGC, Kurian AW, Laronga C, Litton JK, Mak JS, LCGC, Menendez CS, Merajver SD, Norquist BS, Offit K, Pederson HJ, Reiser G, CGC, Senter-Jamieson L, CGC, Shannon KM, Shatsky R, Visvanathan K, Weitzel JN, Wick MJ, Wisinski KB, Yurgelun MB, Darlow SD, Dwyer MA. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 19(1):77-102, 2021. e-Pub 2021. PMID: 33406487.
61. Litton JK, Hurvitz SA, Mina LA, Rugo HS, Lee KH, Gonçalves A, Diab S, Woodward N, Goodwin A, Yerushalmi R, Roché H, Im YH, Eiermann W, Quek RGW, Usari T, Lanzalone S, Czibere A, Blum JL, Martin M, Ettl J. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol 31(11):1526-1535, 2020. e-Pub 2020. PMID: 32828825.
62. Yu Y, Elmeliegy M, Litton JK, Tudor IC, Czibere A, Zheng J, Wang DD. Talazoparib Exposure-Efficacy Analysis in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA Trial. J Clin Pharmacol 60(10):1324-1333, 2020. e-Pub 2020. PMID: 32468579.
63. Elmeliegy M, Yu Y, Litton JK, Czibere A, Wilson GG, Tudor IC, Zheng J, Wang DD. Exposure-Safety Analyses of Talazoparib in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA and ABRAZO Trials. J Clin Pharmacol 60(10):1334-1343, 2020. e-Pub 2020. PMID: 32468645.
64. Clifton GT, Hale D, Vreeland TJ, Hickerson AT, Litton JK, Alatrash G, Murthy RK, Qiao N, Philips AV, Lukas JJ, Holmes JP, Peoples GE, Mittendorf EA. Results of a randomized phase IIb trial of nelipepimut-S + trastuzumab vs trastuzumab to prevent recurrences in high-risk HER2 low-expressing breast cancer patients. Clin Cancer Res 26(11):2515-2523, 2020. e-Pub 2020. PMID: 32071118.
65. Brown TA, Mittendorf EA, Hale DF, Myers JW, Peace KM, Jackson DO, Greene JM, Vreeland TJ, Clifton GT, Ardavanis A, Litton JK, Shumway NM, Symanowski J, Murray JL, Ponniah S, Anastasopoulou EA, Pistamaltzian NF, Baxevanis CN, Perez SA, Papamichail M, Peoples GE. Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence. Breast Cancer Res Treat 181(2):391-401, 2020. e-Pub 2020. PMID: 32323103.
66. Brown TA, Mittendorf EA, Hale DF, Myers JW, Peace KM, Jackson DO, Greene JM, Vreeland TJ, Clifton GT, Ardavanis A, Litton JK, Shumway NM, Symanowski J, Murray JL, Ponniah S, Anastasopoulou EA, Pistamaltzian NF, Baxevanis CN, Perez SA, Papamichail M, Peoples GE. Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence. Breast Cancer Res Treat 181(2):391-401, 2020. e-Pub 2020. PMID: 32323103.
67. Tung NM, Boughey JC, Pierce LJ, Robson ME, Bedrosian I, Dietz JR, Dragun A, Gelpi JB, Hofstatter EW, Isaacs CJ, Jatoi I, Kennedy E, Litton JK, Mayr NA, Qamar RD, Trombetta MG, Harvey BE, Somerfield MR, Zakalik D. Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline. J Clin Oncol 38(18):2080-2106, 2020. e-Pub 2020. PMID: 32243226.
68. Pal T, Agnese D, Daly M, La Spada A, Litton J, Wick M, Klugman S, Esplin ED, Jarvik GP, Practice P, GuidelinesCommittee. Points to consider: Is there evidence to support BRCA1/2 and other inherited breast cancer genetic testing for all breast cancer patients? A statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med 22(4):681-685, 2020. e-Pub 2020. PMID: 31831881.
69. Emborgo TS, Saporito D, Muse KI, Barrera AMG, Litton JK, Lu KH, Arun BK. Prospective evaluation of universal BRCA testing for women with triple-negative breast cancer. JNCI Cancer Spectr eCollection-20;4(2):pkaa002. doi: 10.1093/jncics/pkaa002(2):pkaa002, 2020. e-Pub 2020. PMID: 32211581.
70. Daly MB, Pilarski R, Yurgelun MB, Berry MP, Buys SS, Dickson P, Domchek SM, Elkhanany A, Friedman S, Garber JE, Goggins M, Hutton ML, Khan S, Klein C, Kohlmann W, Kurian AW, Laronga C, Litton JK, Mak JS, Menendez CS, Merajver SD, Norquist BS, Offit K, Pal T, Pederson HJ, Reiser G, Shannon KM, Visvanathan K, Weitzel JN, Wick MJ, Wisinski KB, Dwyer MA, Darlow SD. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. J Natl Compr Canc Netw 18(4):380-391, 2020. e-Pub 2020. PMID: 32259785.
71. Hurvitz SA, Gonçalves A, Rugo HS, Lee KH, Fehrenbacher L, Mina LA, Diab S, Blum JL, Chakrabarti J, Elmeliegy M, DeAnnuntis L, Gauthier E, Czibere A, Tudor IC, Quek RGW, Litton JK, Ettl J. Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial. Oncologist 25(3):e439-e450, 2020. e-Pub 2020. PMID: 32162822.
72. Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Mina LA, Diab S, Woodward NE, Yerushalmi R, Goodwin A, Blum JL, Martin M, Quek RGW, Tudor IC, Bhattacharyya H, Gauthier E, Litton JK, Eiermann W. Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy. JNCI Cancer Spectr 4(1):pkz085, 2020. e-Pub 2020. PMID: 32337496.
73. Litton JK, Scoggins ME, Hess KR, Adrada BE, Murthy RK, Damodaran S, DeSnyder SM, Brewster AM, Barcenas CH, Valero V, Whitman GJ, Schwartz-Gomez J, Mittendorf EA, Thompson AM, Helgason T, Ibrahim N, Piwnica-Worms H, Moulder SL, Arun BK. Neoadjuvant talazoparib for patients with operable breast cancer with a germline BRCA pathogenic variant. J Clin Oncol 38(5):388-394, 2020. e-Pub 2020. PMID: 31461380.
74. Chu YY, Yam C, Chen MK, Chan LC, Xiao M, Wei YK, Yamaguchi H, Lee PC, Han Y, Nie L, Sun X, Moulder SL, Hess KR, Wang B, Hsu JL, Hortobagyi GN, Litton J, Chang JT, Hung MC. Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer. Am J Cancer Res 10(2):648-661, 2020. e-Pub 2020. PMID: 32195033.
75. Bergom C, West CM, Higginson DS, Abazeed ME, Arun B, Bentzen SM, Bernstein JL, Evans JD, Gerber NK, Kerns SL, Keen J, Litton JK, Reiner AS, Riaz N, Rosenstein BS, Sawakuchi GO, Shaitelman SF, Powell SN, Woodward WA. The Implications of Genetic Testing on Radiation Therapy Decisions: A Guide for Radiation Oncologists. Int J Radiat Oncol Biol Phys 105(4):698-712, 2019. e-Pub 2019. PMID: 31381960.
76. Hurvitz SA, Gonçalves A, Rugo HS, Lee KH, Fehrenbacher L, Mina LA, Diab S, Blum JL, Chakrabarti J, Elmeliegy M, DeAnnuntis L, Gauthier E, Czibere A, Tudor IC, Quek RGW, Litton JK, Ettl J. Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: Detailed safety analyses from the phase III EMBRACA trial. Oncologist, 2019. e-Pub 2019. PMID: 31767793.
77. Page DB, Bear H, Prabhakaran S, Gatti-Mays ME, Thomas A, Cobain E, McArthur H, Balko JM, Gameiro SR, Nanda R, Gulley JL, Kalinsky K, White J, Litton J, Chmura SJ, Polley MY, Vincent B, Cescon DW, Disis ML, Sparano JA, Mittendorf EA, Adams S. Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer. NPJ Breast Cancer(5):34, 2019. e-Pub 2019. PMID: 31602395.
78. Xing Y, Lin NU, Maurer MA, Chen H, Mahvash A, Sahin A, Akcakanat A, Li Y, Abramson V, Litton J, Chavez-MacGregor M, Valero V, Piha-Paul SA, Hong D, Do KA, Tarco E, Riall D, Eterovic AK, Wulf GM, Cantley LC, Mills GB, Doyle LA, Winer E, Hortobagyi GN, Gonzalez-Angulo AM, Meric-Bernstam F. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Res 21(1):78, 2019. e-Pub 2019. PMID: 31277699.
79. Clifton K, Min Y, Kimmel J, Litton J, Tripathy D, Karuturi M. Progression-free survival (PFS) and toxicities of palbociclib in a geriatric population. Breast Cancer Res Treat 175(3):667-674, 2019. e-Pub 2019. PMID: 30835017.
80. Garber HR, Litton JK. Integrating poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of early breast cancer. Curr Opin Oncol 31(3):247-255, 2019. e-Pub 2019. PMID: 30789866.
81. Adams S, Gatti-Mays ME, Kalinsky K, Korde LA, Sharon E, Amiri-Kordestani L, Bear H, McArthur HL, Frank E, Perlmutter J, Page DB, Vincent B, Hayes JF, Gulley JL, Litton JK, Hortobagyi GN, Chia S, Krop I, White J, Sparano J, Disis ML, Mittendorf EA. Current landscape of immunotherapy in breast cancer: A review. JAMA Oncol, 2019. e-Pub 2019. PMID: 30973611.
82. Clifton GT, Peace KM, Holmes JP, Vreeland TJ, Hale DF, Herbert GS, Litton JK, Murthy RK, Lukas J, Peoples GE, Mittendorf Elizabeth A. Initial safety analysis of a randomized phase II trial of nelipepimut-S + GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumors. Clin Immunol 201:48-54, 2019. e-Pub 2019. PMID: 30817999.
83. Dumbrava EI, Brusco L, Daniels M, Wathoo C, Shaw K, Lu K, Zheng X, Strong L, Litton J, Arun B, Eterovic AK, Routbort M, Patel K, Qi Y, Piha-Paul S, Subbiah V, Hong D, Rodon J, Kopetz S, Mendelsohn J, Mills GB, Chen K, Meric-Bernstam F. Expanded analysis of secondary germline findings from matched tumor/normal sequencing identifies additional clinically significant mutations. JCO Precis Oncol, 2019. e-Pub 2019. PMID: 31517177.
84. Litton JK, Burstein HJ, Turner NC. Molecular testing in breast cancer. Am Soc Clin Oncol Educ Book 39:e1-e7, 2019. e-Pub 2019. PMID: 31099622.
85. Sinn BV, Fu C, Lau R, Litton J, Tsai TH, Murthy R, Tam A, Andreopoulou E, Gong Y, Murthy R, Gould R, Zhang Y, King TA, Viale A, Andrade V, Giri D, Salgado R, Laios I, Sotiriou C, Marginean EC, Kwiatkowski DN, Layman RM, Booser D, Hatzis C, Vicente Valero V, Fraser Symmans W. SETER/PR: A robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer. NPJ Breast Cancer 5:16, 2019. e-Pub 2019. PMID: 31231679.
86. Johnson RH, Anders CK, Litton JK, Ruddy KJ, Bleyer A. Breast cancer in adolescents and young adults. Pediatr Blood Cancer 65(12):e2739, 2018. e-Pub 2018. PMID: 30156052.
87. Murthy RK, Raghavendra AS, Hess KR, Fujii T, Lim B, Barcenas CH, Zhang H, Chavez-Mac-Gregor M, Mittendorf EA, Litton JK, Giordano SH, Thompson AM, Valero V, Moulder SL, Tripathy D, Ueno NT. Neoadjuvant pertuzumab-containing regimens improve pathologic complete response rates in stage II to III HER-2/neu-positive breast cancer: A retrospective, single institution experience. Clin Breast Cancer 18(6):e1283-e1288, 2018. e-Pub 2018. PMID: 30077429.
88. Basho RK, Yam C, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Hong D, Kurzrock R, Hortobagyi GN, Janku F, Moulder SL. Comparative effectiveness of an mTOR-based systemic therapy regimen in advanced, metaplastic and nonmetaplastic triple-negative breast cancer. Oncologist 23(11):1300-09, 2018. e-Pub 2018. PMID: 30139837.
89. Parkes A, Warneke CL, Clifton K, Al-Awadhi A, Oke O, Pestana RC, Alhalabi O, Litton JK, Hortobagyi GN. Prognostic factors in patients with metastatic breast cancer with bone-only metastases. Oncologist 23(11):1282-88, 2018. e-Pub 2018. PMID: 30120166.
90. Jackson DO, Trappey FA, Clifton GT, Vreeland TJ, Peace KM, Hale DF, Litton JK, Murray JL, Perez SA, Papamichail M, Mittendorf EA, Peoples GE. Effects of HLA status and HER2 status on outcomes in breast cancer patients at risk for recurrence-implications for vaccine trial design. Clin Immunol 195:28-35, 2018. e-Pub 2018. PMID: 30025819.
91. Ettl J, Quek RGW, Lee KH, Rugo HS, Hurvits S, Goncalves A, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roche H, Im YH, Markova D, Bhattacharyya H, Hannah AL, Eirmann W, Blum JL, Litton JK. Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: Patient-reported outcomes from the EMBRACA phase III trial. Annls of Oncol 29(9):1939-47, 2018. e-Pub 2018. PMID: 30124753.
92. Cha JH, Yang WH, Xia W, Wei Y, Chan LC, Lim SO, Li CW, Kim T, Chang SS, Lee HH, Hsu JL, Wang HL, Kuo CW, Chang WC, Hadad S, Purdie CA, McCoy AM, Cai S, Tu Y, Litton JK, Mittendorf EA, Moulder SL, Symmans WF, Thompson AM, Piwnica-Worms H, Chen CH, Khoo KH, Hung MC. Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of pd-l1 71(4):606-620 e7, 2018. e-Pub 2018. PMID: 30118680.
93. Litton JK, Rugo HS, Ettl J, Hurvitz SA, Goncalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roche H, Im YH, Quek RGW, Markova D, Tudor JC, Hannak AL, Eiermann W, Blum JL. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med 379(8):753-763, 2018. e-Pub 2018. PMID: 30110579.
94. Vreeland TJ, Litton JK, Qiao N, Philips AV, Alatrash G, Hale DF, Jackson DO, Peace KM, Greene JM, Berry JS, Clifton GT, Peoples GE, Mittendorf EA. Phase Ib trial of folate binding protein (FBP)-derived peptide vaccines, E39 and an attenuated version, E39': An analysis of safety and immune response. Clin Immunol 192:6-13, 2018. e-Pub 2018. PMID: 29574039.
95. Clifton K, Barnett C, Martinez A, Karuturi M, Saleem S, Litton J. Severe hyponatremia following cyclophosphamide infusion in breast cancer patients. Breast J 24(4):691-692, 2018. e-Pub 2018.
96. Clifton K, Gutierrez-Barrera A, Ma J, Jr BR, Litton J, Kuerer H, Moulder S, Albarracin C, Hortobagyi G, Arun B. Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations. Breast Cancer Res Treat 170(1):101-109, 2018. e-Pub 2018. PMID: 29470805.
97. Elsayegh N, Webster RD, Gutierrez Barrera AM, Lin H, Kuerer HM, Litton JK, Bedrosian I, Arun BK. Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer. Cancer Med 7(6):2718-2726, 2018. e-Pub 2018. PMID: 29733510.
98. Kogawa T, Fujii T, Fouad TM, Liu DD, Harano K, Masuda H, Iwase T, Barnett C, Park YS, Lim B, Tripathy D, Litton JK, Ueno NT. Impact of change in body mass index during neoadjuvant chemotherapy and survival among breast cancer subtypes. Breast Cancer Res Treat, 2018. e-Pub 2018. PMID: 29915946.
99. Chambers MS, Rugo HS, Litton JK, Meiller TF. Stomatitis associated with mammalian target of rapamycin inhibition: A review of pathogenesis, prevention, treatment, and clinical implications for oral practice in metastatic breast cancer. J Am Dent Assoc 149(4):291-8, 2018. e-Pub 2018. PMID: 29439772.
100. Carey JP, Karakas C, Bui T, Chen X, Vijayaraghavan S, Zhao Y, Wang J, Mikule K, Litton JK, Hunt KK, Keyomarsi K. Synthetic lethality of PARP inhibitors in combination with MYC blockade is independent of BRCA status in triple negative breast cancer. Cancer Res 78(3):742-57, 2018. e-Pub 2018. PMID: 29180466.
101. Parkes A, Clifton K, Al-Awadhi A, Oke O, Warneke CL, Litton JK, Hortobagyi GN. Characterization of bone only metastasis patients with respect to tumor subtypes. NPJ Breast Cancer 4(2), 2018. e-Pub 2018. PMID: 29387785.
102. Litton JK, Scoggins M, Ramirez DL, Murthy RK, Whitman GJ, Hess KR, Adrada BE, Moulder SL, Barcenas CH, Valero V, Gomez JS, Mittendorf EA, Thompson A, Helgason T, Mills GB, Piwnica-Worms H, Arun BK. A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity. NPJ Breast Cancer 3:49, 2017. e-Pub 2017. PMID: 29238749.
103. Evans KW, Yuca E, Akcakanat A, Scott SM, Arango NP, Zheng X, Chen K, Tapia C, Tarco E, Eterovic AK, Black DM, Litton JK, Yap TA, Tripathy D, Mills GB, Meric-Bernstam F. A population of heterogeneous breast cancer patient-derived xenografts demonstrate broad activity of PARP inhibitor in BRCA1/2 wild-type tumors. Clin Cancer Res 23(21):6468-6477, 2017. e-Pub 2017. PMID: 29093017.
104. Gutierrez Barrera AM, Fouad TM, Song J, Webster R, Elsayegh N, Wood AL, Demir A, Litton JK, Ueno NT, Arun BK. BRCA mutations in women with inflammatory breast cancer. Cancer, 2017. e-Pub 2017. PMID: 29044548.
105. Fujii T, Kogawa T, Dong W, Sahin AA, Moulder S, Litton JK, Tripathy D, Iwamoto T, Hunt KK, Pusztai L, Lim B, Shen Y, Ueno NT. Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer. Ann Oncol 26(10):2420-2428, 2017. e-Pub 2017. PMID: 28961844.
106. Bashour SI, Doostan I, Keyomarsi K, Valero V, Ueno NT, Brown PH, Litton JK, Koenig KB, Karuturi M, Abouharb S, Tripathy D, Moulder-Thompson SL, Ibrahim NK. Rapid breast cancer disease progression following cyclin dependent kinase 4 and 6 inhibitor discontinuation. J Cancer 8(11):2004-9, 2017. e-Pub 2017. PMID: 28819400.
107. Parkes A, Arun BK, Litton JK. Systemic treatment strategies for patients with hereditary breast cancer syndromes. Oncologist 22(6):655-666, 2017. e-Pub 2017. PMID: 28469042.
108. Cropper C, Woodson A, Arun B, Barcenas C, Litton J, Noblin S, Liu D, Park M, Daniels M. Evaluating the NCCN clinical criteria for recommending BRCA1 and BRCA2 genetic testing in breast cancer patients. J Natl Compr Canc Netw 15(6):797-803, 2017. e-Pub 2017. PMID: 28596260.
109. Basho RK, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Herbrich SM, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Ibrahim NK, JLrd M, Koenig KB, Hong D, Subbiah V, Kurzrock R, Janku F, Moulder SL. Targeting the PI3K/AKT/mTOR pathway for the treatment of mesenchymal triple-negative breast cancer: Evidence from a phase 1 trial of mTOR inhibition in combination with liposomal doxorubicin and bevacizumab. JAMA Oncol 3(4):509-15, 2017. e-Pub 2017. PMID: 27893038.
110. Rugo HS, Seneviratne L, Beck T, Glaspy JA, Peguero JA, Pluard TJ, Dhillon N, Hwang LC, Nangia C, Mayer IA, Meiller TF, Chambers MS, Sweetman RW, Sabo R, Litton JK. Prevention of everolimus/exemestane–related stomatitis in women with hormone receptor–positive metastatic breast cancer using dexamethasone mouthwash: Results from the phase 2, single-arm SWISH trial. Lancet Onc, 2017. e-Pub 2017. PMID: 28314691.
111. Travis Clifton G, Litton JK, Arrington K, Ponniah S, Ibrahim NK, Gall V, Alatrash G, Peoples GE, Mittendorf EA. Results of a phase Ib trial of combination immunotherapy with a CD8+ T cell eliciting vaccine and trastuzumab in breast cancer patients. Ann Surg Oncol 24(8):2161-7, 2017. e-Pub 2017. PMID: 28315060.
112. Daly MB, Pilarski R, Berry M, Buys SS, Farmer M, Friedman S, Garber JE, Kauff ND, Khan S, Klein C, Kohlmann W, Kurian A, Litton JK, Madlensky L, Merajver SD, Offit K, Pal T, Reiser G, Shannon KM, Swisher E, Vinayak S, Voian NC, Weitzel JN, Wick MJ, Wiesner GL, Dwyer M, Darlow S. NCCN guidelines insights: Genetic/familial high-risk assessment: Breast and ovarian, version 2.2017. J Natl Compr Canc Netw 15(1):9-20, 2017. e-Pub 2017. PMID: 28040716.
113. Basho RK, Gagliato DM, Ueno NT, Wathoo C, Chen H, Shariati M, Wei C, Alvarez RH, Moulder SL, Sahin AA, Roy-Chowdhuri S, Chavez-MacGregor M, Litton JK, Valero V, Luthra R, Zeng J, Shaw KR, Mendelsohn J, Mills GB, Tripathy D, Meric-Bernstam F. Clinical outcomes based on multigene profiling in metastatic breast cancer patients. Oncotarget, 2016. e-Pub 2016. PMID: 27806348.
114. Mittendorf EA, Ardavanis A, Symanowski J, Murray JL, Shumway NM, Litton JK, Hale DF, Perez SA, Anastasopoulou EA, Pistamaltzian NF, Ponniah S, Baxevanis CN, von Hofe E, Papamichail M, Peoples GE. Primary analysis of a prospective, randomised, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence. Ann Oncol 27(7):1241-8, 2016. e-Pub 2016. PMID: 27029708.
115. Streff H, Profato J, Ye Y, Nebgen D, Peterson SK, Singletary C, Arun BK, Litton JK. Cancer incidence in first and second degree relatives of BRCA1 and BRCA2 mutation carriers. Oncologist 21(7):869-74, 2016. e-Pub 2016. PMID: 27306910.
116. Arun B, Gong Y, Liu D, Litton JK, Gutierrez-Barrera AM, Jack Lee J, Vornik L, Ibrahim NK, Cornelison T, Hortobagyi GN, Heckman-Stoddard BM, Koenig KB, Alvarez RR, Murray JL, Valero V, Lippman SM, Brown P, Sneige N. Phase I biomarker modulation study of storvastatin in women at increased risk for breast cancer. Breast Cancer Res Treat, 2016. e-Pub 2016. PMID: 27287781.
117. Vila J, Mittendorf EA, Farante G, Bassett RL, Veronesi P, Galimberti V, Peradze N, Stauder MC, Chavez-MacGregor M, Litton JF, Huo L, Kuerer HM, Hunt KK, Caudle AS. Nomograms for predicting axillary response to neoadjuvant chemotherapy in clinically node-positive patients with breast cancer. Ann Surg Oncol, 2016. e-Pub 2016. PMID: 27216742.
118. Elsayegh N, Barrera AM, Muse KI, Lin H, Kuerer HM, Helm M, Litton JK, Arun BK. Evaluation of BRCAPRO risk assessment model in patients with ductal carcinoma in situ who underwent clinical BRCA genetic testing. Front Genet 27(7):71, 2016. e-Pub 2016. PMID: 27200080.
119. Swisher SK, Vila J, Tucker SL, Bedrosian I, Shaitelman SF, Litton JK, Smith BD, Caudle AS, Kuerer HM, Mittendorf EA. Local-regional control according to breast cancer subtype and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. Annals of Surg Onc 23(3):749-56, 2016. e-Pub 2016. PMID: 26511263.
120. Daly MB, Pilarski R, Axilbund JE, Berry M, Buys SS, Crawford B, Farmer M, Friedman S, Garber JE, Khan S, Klein C, Kohlmann W, Kurian A, Litton JK, Madlensky L, Marcom PK, Merajver SD, Offit K, Pal T, Rana H, Reiser G, Robson ME, Shannon KM, Swisher E, Voian NC, Weitzel JN, Whelan A, Wick MJ, Wiesner GL, Dwyer M, Kumar R, Darlow S. Genetic/familial high-risk assessment: Breast and ovarian, version 2.2015. J Natl Compr Canc Netw 14(2):153-62, 2016. e-Pub 2016. PMID: 26850485.
121. Meric-Bernstam F, Brusco L, Daniels M, Wathoo C, Bailey A, Strong L, Shaw K, Lu K, Qi Y, Zhao H, Lara-Guerra H, Litton J, Arun B, Eterovic AK, Aytac U, Routbort M, Subbiah V, Janku F, Davies MA, Kopetz S, Mendelsohn J, Mills GB, Chen K. Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. Ann of Oncol 27(5):795-800, 2016. e-Pub 2016. PMID: 26787237.
122. Kehl KL, Shen C, Litton JK, Arun B, Giordano SH. Rates of BRCA1/2 mutation testing among young survivors of breast cancer. Breast Cancer Res Treat 155(1):165-73, 2016. e-Pub 2016. PMID: 26706041.
123. Gonzalez-Angulo AM, Lei X, Alvarez RH, Green MC, Murray JL, Valero V, Koenig KB, Ibrahim NK, Litton JK, Nair L, Krishnamurthy S, Hortobagyi GN, Meric-Bernstam F. Phase II randomized study of ixabepilone vs. observation in patients with significant residual disease after neoadjuvant systemic therapy for HER2-negative breast cancer. Clin Breast Cancer 15(5):325-31, 2015. e-Pub 2015. PMID: 25913905.
124. Sanford RA, Song J, Gutierrez-Barrera AM, Profato J, Woodson A, Litton JK, Bedrosian I, Albarracin CT, Valero V, Arun B. High incidence of germline BRCA mutation in patients with ER low-positive/PR low-positive/HER-2 neu negative tumors. Cancer, 2015. e-Pub 2015. PMID: 26280679.
125. Elsayegh N, Profato J, Barrera AM, Lin H, Kuerer HM, Ardic C, Litton JK, Tripathy D, Arun BK. Predictors that influence election of contralateral prophylactic mastectomy among women with ductal carcinoma in situ who are BRCA-negative. J Cancer 6(7):610-5, 2015. e-Pub 2015. PMID: 26078790.
126. Lu D, F Eckhardt B, Lim B, Moulder S, Litton J, Ueno NT. Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?. Oncotarget, 2015. e-Pub 2015. PMID: 25973541.
127. Bayraktar S, Jackson M, Gutierrez Barrera AM, Liu D, Meric-Bernstam F, Brandt A, Woodson A, Litton J, Lu KH, Valero V, Arun BK. Genotype-phenotype correlations by ethnicity and mutation location in BRCA mutation carriers. Breast J 21(3):260-7, 2015. e-Pub 2015. PMID: 25789811.
128. Parinyanitikul N, Lei X, Chavez-MacGregor M, Liu S, Mittendorf EA, Litton JK, Woodward W, Zhang AH, Hortobagyi GN, Valero V, Meric-Bernstam F, Gonzalez-Angulo AM. Receptor status change from primary to residual breast cancer after neoadjuvant chemotherapy and analysis of survival outcomes. Clin Breast Cancer 15(2):153-60, 2015. e-Pub 2015. PMID: 25454687.
129. Mitri ZI, Jackson M, Garby C, Song J, Giordano SH, Hortobagyi GN, Singletary CN, Hasmi SS, Arun BK, Litton JK. BRCAPRO 6.0 model in male patients presenting for BRCA testing. Oncologist 20(6):593-7, 2015. e-Pub 2015. PMID: 25948675.
130. Mersch J, Jackson MA, Park M, Nebgen D, Peterson SK, Singletary C, Arun BK, Litton JK. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer 121(2):269-75, 2015. e-Pub 2015. PMID: 25224030.
131. Kogawa T, Fouad TM, Wei C, Masuda H, Kai K, Fujii T, El-Zein R, Chavez-MacGregor M, Litton JK, Brewster A, Alvarez RH, Hortobagyi GN, Valero V, Theriault R, Ueno NT. Association of body mass index changes during neoadjuvant chemotherapy with pathologic complete response and clinical outcomes in patients with locally advanced breast cancer. J Cancer 6(4):310-8, 2015. e-Pub 2015. PMID: 25767600.
132. Murthy RK, Theriault RL, Barnett CM, Hodge S, Ramirez MM, Milbourne A, Rimes SA, Hortobagyi GN, Valero V, Litton JK. Outcomes of children exposed in utero to chemotherapy for breast cancer. Breast Cancer Research 16(6):3414, 2014. e-Pub 2014. PMID: 25547133.
133. Woodson AH, Muse KI, Lin H, Jackson M, Mattair DN, Schover L, Woodard T, McKenzie L, Theriault RL, Hortobágyi GN, Arun B, Peterson SK, Profato J, Litton JK. Breast cancer, BRCA mutations, and attitudes regarding pregnancy and preimplantation genetic diagnosis. Oncologist 19(8):797-804, 2014. e-Pub 2014. PMID: 24951607.
134. Gonzalez-Angulo AM, Akcakanat A, Liu S, Green MC, Murray JL, Chen H, Palla SL, Koenig KB, Brewster AM, Valero V, Ibrahim NK, Moulder-Thompson S, Litton JK, Tarco E, Moore J, Flores P, Crawford D, Dryden MJ, Symmans WF, Sahin A, Giordano SH, Pusztai L, Do KA, Mills GB, Hortobagyi GN, Meric-Bernstam F. Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer. Ann Oncology 25(6):1122-7, 2014. e-Pub 2014. PMID: 24669015.
135. Jackson SA, Davis AA, Li J, Yi N, McCormick SR, Grant C, Fallen T, Crawford B, Loranger K, Litton J, Arun B, Vande Wydeven K, Sidani A, Farmer K, Sanders M, Hoskins K, Nussbaum R, Esserman L, Garber JE, Kaklamani VG, Genetics Group TNC. Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2. Cancer 120(10):1557-64, 2014. e-Pub 2014. PMID: 24522996.
136. Elsayegh N, Kuerer HM, Lin H, Gutierrez Barrera AM, Jackson M, Muse KI, Litton JK, Albarracin C, Afrough A, Hortobagyi GN, Arun BK. Predictors that Influence contralateral prophylactic mastectomy election among women with ductal carcinoma in situ who were evaluated for BRCA genetic testing. Ann Surg Oncol, 2014. e-Pub 2014. PMID: 24796968.
137. Morrow PK, Broxson AC, Munsell MF, Basen-Enquist K, Rosenblum CK, Schover L, Nguyen LH, Hsu L, Castillo L, Hahn KM, Litton JK, Mattair DM, Hortobagyi GN. Effect of age and race upon quality of young breast cancer survivors. Clin Breast Cancer 14(2):e 21-31, 2014. e-Pub 2014. PMID: 24461458.
138. André F, O'Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G, Masuda N, Wilks S, Arena F, Isaacs C, Yap YS, Papai Z, Lang I, Armstrong A, Lerzo G, White M, Shen K, Litton J, Chen D, Zhang Y, Ali S, Taran T, Gianni L. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): A randomized, double-blind, placebo-controlled phase 3 trial. Lancet Oncol, 2014. e-Pub 2014. PMID: 24742739.
139. Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM, Akcakanat A, Chawla A, Curran M, Hwu P, Sharma P, Litton JK, Molldrem JJ, Alatrash G. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res 2(4):361-70, 2014. PMID: 24764583.
140. Weksberg DC, Allen PK, Hoffman KE, Litton JK, Strom EA, Shah RR, Kuerer HM, Hunt KK, Buchholz TA, Mittendorf EA. Outcomes and predictive factors for salvage therapy after local--regional recurrence following neoadjuvant chemotherapy and breast conserving therapy. Ann Surg Oncol 20(11):3430-7, 2013. e-Pub 2013. PMID: 23720073.
141. Chen JQ, Bao Y, Lee J, Murray JL, Litton JK, Xiao L, Zhou R, Wu Y, Shen XY, Zhang H, Sahin AA, Katz RL, Bondy ML, Berinstein NL, Hortobagyi GN, Radvanyi LG. Prognostic value of the trichorhinophalangeal syndrome-1 (TRPS-1), A GATA family transcription factor, in early-stage breast cancer. Ann Oncol 24(10):2534-42, 2013. e-Pub 2013. PMID: 23729783.
142. Rich TA, Liu M, Etzel CJ, Bannon SA, Mork ME, Ready K, Saraiya DS, Grubbs EG, Perrier ND, Lu ND, Lu KH, Arun BK, Woodard TL, Schover LR, Litton JK. Comparison of attitudes regarding preimplantation genetic diagnosis among patients with hereditary cancer syndromes. Fam Cancer 13(2):291-9, 2013. e-Pub 2013. PMID: 24072553.
143. Yennurajalingam S, Frisbee-Hume S, Palmer JL, Delgado-Guay MO, Bull J, Phan AT, Tannir NM, Litton JK, Reddy A, Hui D, Dalal S, Massie L, Reddy SK, Bruera E. Reduction of cancer-related fatigue with dexamethasone: A double-blind, randomized, placebo-controlled trial in advanced cancer patients. J Clin Oncol 31(25):3076-82, 2013. e-Pub 2013. PMID: 23897970.
144. Chae YK, Brown EN, Lei X, Melhem-Bertrandt A, Giordano SH, Litton JK, Hortobagyi GN, Gonzalez-Angulo AM, Chavez-MacGregor M. Use of ACE inhibitors and angiotensin receptor blockers and primary breast cancer outcomes. J Cancer 4(7):549-56, 2013. e-Pub 2013. PMID: 23983819.
145. Woodson AH, Profarto JL, Muse KI, Litton JK. Breast cancer in the young: Role of the geneticist. J Thorac Dis 5(Suppl 1):S19-26, 2013. e-Pub 2013. PMID: 23819023.
146. Woodard TL, Litton JK. Fertility preservation in women with breast cancer: Challenges and opportunities. Oncology (Williston Park) 27(6):544, 546, 2013. e-Pub 2013. PMID: 23909068.
147. Meric-Bernstam F, Gutierrez-Barrera AM, Litton J, Mellor-Crummey L, Ready K, Gonzalez-Angulo AM, Lu KH, Hortobagyi GN, Arun BK. Genotype in BRCA-associated breast cancers. Breast J 19(1):87-91, 2013. e-Pub 2013. PMID: 23231005.
148. Bayraktar S, Gutierrez Barrera AM, Liu D, Pusztai L, Litton J, Valero V, Hunt K, Hortobagyi GN, Wu Y, Symmans F, Arun B. USP-11 as a predictive and prognostic factor following neoadjuvant therapy in women with breast cancer. Cancer J 19(1):10-7, 2013. e-Pub 2013. PMID: 23337751.
149. Litton JK, Warneke CL Hahn KM, Palla SL, Kuerer HM, Perkins GH, Mittendorf EA, Barnett C, Gonzalez-Angulo AM, Hortobagyi GN, Theriault RL. Case control study of women treated with chemotherapy for breast cancer during pregnancy as compared with non-pregnant breast cancer patients. Oncologist 18(4):369-76, 2013. e-Pub 2013. PMID: 23576478.
150. Bayraktar S, Gutierrez-Barrera AM, Lin H, Elsayegh N, Tasbas T, Litton JK, Ibrahim NK, Morrow PK, Green M, Valero V, Booser DJ, Hortobagyi GN, Arun BK. Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations. J Clin Exp Mets 30(5):631-42, 2013. e-Pub 2013. PMID: 23370825.
151. Kim MM, Allen P, Gonzalez-Angulo AM, Woodward WA, Meric-Bernstam F, Buzdar AU, Hunt KK, Kuerer HM, Litton JK, Hortobagyi GN, Buchholz TA, Mittendorf EA. Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer. Ann Oncol 24(8):1999-2004, 2013. e-Pub 2013. PMID: 23562929.
152. Dawood S, Lei X, Litton JK, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM. Impact of body mass index on survival outcome among women with early stage triple-negative breast cancer. Clin Breast Cancer 12(5):364-72, 2012. e-Pub 2012. PMID: 23040004.
153. Dawood S, Lei X, Litton JK, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM. Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer. Cancer 118(19):4652-9, 2012. e-Pub 2012. PMID: 22359359.
154. Kuerer HM, Lari SA, Arun BK, Hu CY, Brewster A, Mittendorf EA, Albarracin CT, Babiera GV, Caudle AS, Wagner JL, Litton JK, Bedrosian I, Meric-Bernstam F, Lucci A, Hunt KK. Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass. Breast Cancer Res Treat 133(3):1131-41, 2012. e-Pub 2012. PMID: 22392043.
155. Caudle AS, Yu TK, Tucker SL, Bedrosian I, Litton JK, Gonzalez-Angulo AM, Hoffman K, Meric-Bernstam F, Hunt KK, Buchholz TA, Mittendorf EA. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. Breast Cancer Res 14(3):R83, 2012. e-Pub 2012. PMID: 22621334.
156. Bayraktar S, Hernandez-Aya LF, Lei X, Meric-Bernstam F, Litton JK, Hsu L, Hortobagyi GN, Gonzalez-Angulo AM. Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer 118(5):1202-11, 2012. e-Pub 2012. PMID: 21800293.
157. Bayraktar S, Elsayegh N, Gutierrez Barrera AM, Lin H, Kuerer H, Tasbas T, Muse KI, Ready K, Litton JK, Meric-Bernstam F, Hortobagyi GN, Albarracin CT, Arun B. Predictive factors for BRCA1/2 mutations in women with ductal carcinoma in situ. Cancer 118(6):1515-22, 2012. e-Pub 2012. PMID: 22009639.
158. Melhem-Bertrandt A, Bojadzieva J, Ready KJ, Obeid E, Liu DD, Gutierrez-Barrera AM, Litton JK, Olopade OI, Hortobagyi GN, Strong LC, Arun BK. Early onset HER2-positive breast cancer is associated with germline TP53 mutations. Cancer 118(4):908-13, 2012. e-Pub 2012. PMID: 21761402.
159. Chavez-MacGregor M, Brown E, Lei X, Litton JK, Meric-Bernstram F, Mittendorf E, Hernandez L, Valero V, Hortobagyi GN, Gonzalez-Angulo AM. Bisphosphonates and pathologic complete response to taxane and anthracycline-based neoadjuvant chemotherapy in patients with breast cancer. Cancer 118(2):326-32, 2012. e-Pub 2012. PMID: 21590688.
160. Litton JK, Ready K, Chen H, Gutierrez-Barrera A, Etzel CJ, Meric-Bernstam F, Gonzalez-Angulo AM, Le-Petross H, Lu K, Hortobagyi GN, Arun BK. Earlier age of onset of BRCA mutation-related cancers in subsequent generations. Cancer 118(2):321-5, 2012. e-Pub 2012. PMID: 21913181.
161. Del Fabbro E, Parsons H, Warneke CL, Pulivarthi K, Litton JK, Dev R, Palla SL, Brewster A, Bruera E. The relationship between body composition and response to neoadjuvant chemotherapy in women with operable breast cancer. The Oncologist 17(10):1240-5, 2012. e-Pub 2012. PMID: 22903527.
162. Ready K, Arun BK, Schmeler KM, Uyei A, Litton JK, Lu KH, Sun CC, Peterson SK. Communication of BRCA1 and BRCA2 genetic test results to health care providers following genetic testing at a tertiary care center. Fam Cancer 10(4):673-9, 2011. e-Pub 2011. PMID: 21681553.
163. Bayraktar S, Gutierrez-Barrera AM, Liu D, Tasbas T, Akar U, Litton JK, Lin E, Albarracin CT, Meric-Bernstam F, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK. Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treat 130(1):145-53, 2011. e-Pub 2011. PMID: 21830012.
164. Arun B, Bayraktar S, Liu DD, Gutierrez Barrera AM, Atchley D, Pusztai L, Litton JK, Valero V, Meric-Bernstam F, Hortobagyi GN, Albarracin C. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and non-carriers: A single institution experience. J Clin Oncol 29(28):3739-46, 2011. e-Pub 2011. PMID: 21900106.
165. Theriault RL, Litton JK, Mittendorf EA, Chen H, Meric-Bernstam F, Chavez-Macgregor M, Morrow PK, Woodward WA, Sahin A, Hortobagyi GN, Gonzalez-Angulo AM. Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype. Clin Breast Cancer 11(5):325-31, 2011. e-Pub 2011. PMID: 21764391.
166. Adkins FC, Gonzalez-Angulo AM, Lei X, Hernandez-Aya LF, Mittendorf EA, Litton JK, Wagner J, Hunt KK, Woodward WA, Meric-Bernstam F. Triple-negative breast cancer is not a contraindication for breast conservation. Ann Surg Oncol 18(11):3164-73, 2011. e-Pub 2011. PMID: 21947595.
167. Le-Petross HT, Whitman GJ, Atchley DP, Yuan Y, Gutierrez-Barrera A, Hortobagyi GN, Litton JK, Arun BK. Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer. Cancer 117(17):3900-7, 2011. e-Pub 2011. PMID: 21365619.
168. Caudle AS, Hunt KK, Kuerer HM, Meric-Bernstam F, Lucci A, Bedrosian I, Babiera GV, Hwang RF, Ross MI, Feig BW, Hoffman K, Litton JK, Sahin AA, Yang W, Hortobagyi GN, Buchholz TA, Mittendorf EA. Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 study: A practice-changing trial. Ann Surg Oncol 18(9):2407-12, 2011. e-Pub 2011. PMID: 21327455.
169. Sharma R, Rourke LL, Kronowitz SJ, Oh JL, Lucci A, Litton JK, Robb GL, Babiera GV, Mittendorf EA, Hunt KK, Kuerer HM. Management of local-regional recurrence following immediate breast reconstruction in patients with early breast cancer treated without postmastectomy radiotherapy. Plast Reconstr Surg 127(5):1763-72, 2011. e-Pub 2011. PMID: 21532405.
170. Chen JQ, Bao Y, Litton J, Xiao L, Zhang HZ, Warneke CL, Wu Y, Shen X, Wu S, Katz RL, Sahin A, Bondy M, Murray JL, Radvanyi L. Expression and relevance of TRPS-1: A new GATA transcription factor in breast cancer. Horm Cancer 2(2):132-43, 2011. e-Pub 2011. PMID: 21761336.
171. Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, Lanchbury JS, Stemke-Hale K, Hennessy BT, Arun BK, Hortobagyi GN, Do KA, Mills GB, Meric-Bernstam F. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 17(5):1082-9, 2011. e-Pub 2011. PMID: 21233401.
172. Valero V III, Kong AL, Hunt KK, Yi M, Hwang RF, Meric-Bernstam F, Bedrosian I, Ross MI, Babiera GV, Litton JK, Mittendorf EA. Sentinel lymph node dissection is technically feasible in older breast cancer patients. Clin Breast Cancer 10(6):477-82, 2010. e-Pub 2010. PMID: 21147692.
173. Kelly CM, Krishnamurthy S, Bianchini G, Litton JK, Gonzalez-Angulo AM, Hortobagyi GN, Pusztai L. Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers. Cancer 116(22):5161-7, 2010. e-Pub 2010. PMID: 20665886.
174. Chavez-Macgregor M, Litton J, Chen H, Giordano SH, Hudis CA, Wolff AC, Valero V, Hortobagyi GN, Bondy ML, Gonzalez-Angulo AM. Pathologic complete response in breast cancer patients receiving anthracycline-and taxane-based neoadjuvant chemotherapy: Evaluating the effect of race/ethnicity. Cancer 116(17):4168-77, 2010. e-Pub 2010. PMID: 20564153.
175. Yi M, Hunt KK, Arun BK, Bedrosian I, Barrera AG, Do KA, Kuerer HM, Babiera GV, Mittendorf EA, Ready K, Litton J, Meric Bernstam F. Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy. Cancer Prev Res 3(8):1026-34, 2010. e-Pub 2010. PMID: 20647335.
176. Daly MB, Axilbund JE, Buys S, Crawford B, Farrell CD, Friedman S, Garber JE, Goorha S, Gruber SB, Hampel H, Kaklamani V, Kohlmann W, Kurian A, Litton JK, Marcom PK, Nussbaum R, Offit K, Pal T, Pasche B, Pilarski R, Reiser G, Shannon KM, Smith JR, Swisher E, Weitzel JN. Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw 8(5):562-94, 2010. e-Pub 2010. PMID: 20495085.
177. Chen JQ, Litton JK, Xiao L, H-Z Z, Warneke CL, Wu, Y, Shen X, Wu S, Sahin A, Katz R, Bondy M, Hortobagyi GN, Berinstein NL, Murray JL, Radvanyi L. Quantitative immunohistochemical analysis and prognostic significance of TRPS-1, A new GATA transcription factor family member, in breast cancer. Horm Cancer 1(1):21-33, 2010. e-Pub 2010. PMID: 21761348.
178. Silberfein EJ, Hunt KK, Broglio K, Shen J, Sahin A, Le-Petross H, Oh J, Litton J, Hwang RF, Mittendorf EA. Clinicopathologic factors associated with involved margins after breast-conserving surgery for invasive lobular carcinoma. Clin Breast Cancer 10(1):52-8, 2010. e-Pub 2010. PMID: 20133259.
179. Dominici LS, Kuerer HM, Babiera G, Hahn KM, Perkins G, Middleton L, Ramirez MM, Yang W, Hortobagyi GN, Theriault RL, Litton JK. Wound complications from surgery in pregnancy-associated breast cancer (PABC). Breast Dis 31(1):1-5, 2010. e-Pub 2010. PMID: 20519803.
180. Gonzalez-Angulo AM, Litton JK, Broglio KR, Meric-Bernstam F, Rakkhit R, Cardoso F, Peintinger F, Hanrahan EO, Sahin A, Guray M, Larsimont D, Feoli F, Stranzl H, Buchholz TA, Valero V, Theriault R, Piccart-Gebhart M, Ravdin PM, Berry DA, Hortobagyi GN. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 27(34):5700-6, 2009. e-Pub 2009. PMID: 19884543.
181. Litton JK, Westin SN, Ready K, Sun CC, Peterson SK, Meric-Bernstam F, Gonzalez-Angulo AM, Bodurka DC, Lu KH, Hortobagyi GN, Arun BK. Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation. Cancer 115(8):1598-604, 2009. e-Pub 2009. PMID: 19280625.
182. Beadle BM, Woodward WA, Middleton LP, Tereffe W, Strom EA, Litton JK, Meric-Bernstam F, Theriault RL, Buchholz TA, Perkins GH. The impact of pregnancy on breast cancer outcomes in women
183. Beadle BM, Woodward WA, Tucker SL, Outlaw ED, Allen PK, Oh JL, Strom EA, Perkins GH, Tereffe W, Yu TK, Meric-Bernstam F, Litton JK, Buchholz TA. Ten-year recurrence rates in young women with breast cancer by locoregional treatment approach. Int J Radiat Oncol Biol Phys 73(3):734-44, 2009. e-Pub 2009. PMID: 18707822.
184. Eralp Y, Smith TL, Altundag K, Kau SW, Litton JK, Valero V, Buzdar A, Hortobagyi GN, Arun B. Clinical features associated with a favorable outcome following neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger. J Cancer Res Clin Oncol 135(1):141-8, 2009. e-Pub 2009. PMID: 18581139.
185. Litton JK, Theriault RL, Gonzalez-Angulo AM. Breast Cancer diagnosis during pregnancy. Womens Health (Lond Engl) 5:243-249, 2009. e-Pub 2009.
186. Litton JK, Gonzalez-Angulo AM, Warneke CL, Buzdar AU, Kau SW, Bondy M, Mahabir S, Hortobagyi GN, Brewster AM. Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. J Clin Oncol 26(25):4072-7, 2008. e-Pub 2008. PMID: 18757321.
187. Litton JK, Eralp Y, Gonzalez-Angulo AM, Broglio K, Uyei A, Hortobagyi GN, Arun B. Multifocal breast cancer in women < or =35 years old. Cancer 110(7):1445-50, 2007. e-Pub 2007. PMID: 17676585.
188. Shapiro CL, Ervin T, Welles L, Azarnia N, Keating J, Hayes DF. Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. TLC D-99 Study Group. J Clin Oncol 17(5):1435-41, 1999. e-Pub 1999. PMID: 10334528.
189. Shapiro CL, Keating J, Angell JE, Janicek M, Gelman R, Hayes D, LeBoff MS. Monitoring therapeutic response in skeletal metastases using dual-energy X-ray absorptiometry: A prospective feasibility study in breast cancer patients. Cancer Invest 17(8):566-74, 1999. e-Pub 1999. PMID: 10592763.
190. Shapiro CL, Ayash L, Webb IJ, Gelman R, Keating J, Williams L, Demetri G, Clark P, Elias A, Duggan D, Hayes D, Hurd D, Henderson IC. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral blood progenitor cells and filgrastim in advanced breast cancer patients. J Clin Oncol 15(2):674-83, 1997. e-Pub 1997. PMID: 9053493.

Invited Articles

1. Tran G, Helm M, Litton J. Current approach to breast cancer risk reduction for women with hereditary predispositions to breast cancer. Current Breast Cancer Rep 8:165-174, 2016. e-Pub 2016.
2. Rich TA, Woodson AH, Litton J, Arun B. Hereditary breast cancer syndromes and genetic testing. J Surg Oncol 111(1):66-80, 2015. e-Pub 2015. PMID: 25381882.
3. Muse KI, Litton JK. What women need to know about genetic testing for hereditary cancer. Coping with Cancer 8(1):25-7, 2014. e-Pub 2014.
4. Litton JK. Breast cancer and fertility. Curr Treat Options Oncol 13(2):137-45, 2012. e-Pub 2012. PMID: 22396154.
5. Litton JK, Bevers TB, Arun BK. Exemestane in the prevention setting. Ther Adv Med Oncol 4(3):1-6, 2012. e-Pub 2012. PMID: 22590484.
6. Litton JK, Arun BK, Brown PH, Hortobagyi GN. Aromatase inhibitors and breast cancer prevention. Expert Opin Pharmacother 13(3):325-31, 2012. e-Pub 2012. PMID: 22242911.
7. Litton JK. Commentary on presentation management and outcome of 32 patients with PABC: A matched controlled study. Breast Diseases: A Year Book Quarterly 21(2):131-132, 2010. e-Pub 2010.
8. Anders CA, Johnson R, Litton JK, Phillips M, Bleyer A. Breast cancer before 40. Seminars in Oncology 36(3):237-349, 2009. e-Pub 2009.
9. Litton JK, Kelly K, Hunt MD. Management of the contralateral breast in women with newly diagnosed breast cancer. Medscape CME, 2009. e-Pub 2009.
10. Litton JK, Theriault RL. Breast cancer during pregnancy and lactation. UpToDate, 2009. e-Pub 2009.
11. Litton JK. Commentary on variants in the ATM gene associated with a reduced risk of contralateral breast cancer. Breast Diseases: A Year Book Quarterly 20(3):291-292, 2009. e-Pub 2009.

Review Articles

1. Guerra CE, Litton JK, Viswanath CE, Fendrick AM. Multicancer Early Detection Tests at a Crossroads: Commercial Availability Ahead of Definitive Evidence. Am Soc Clin Oncol Educ Book 45(3):e473834, 2025. e-Pub 2025. PMID: 40262060.
2. Hage Chehade C, Gebrael G, Sayegh N, Ozay ZI, Narang A, Crispino T, Golan T, Litton JK, Swami U, Moore KN, Agarwal N. A pan-tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors. CA Cancer J Clin 75(2):141-167, 2025. e-Pub 2025. PMID: 39791278.
3. Abdelhafez AH, Musall BC, Adrada BE, Hess K, Son JB, Hwang KP, Candelaria RP, Santiago L, Whitman GJ, Le-Petross HT, Moseley TW, Arribas E, Lane DL, Scoggins ME, Leung JWT, Mahmoud HS, White JB, Ravenberg EE, Litton JK, Valero V, Wei P, Thompson AM, Moulder SL, Pagel MD, Ma J, Yang WT, Rauch GM. Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC). Breast Cancer Res Treat 185(1):1-12, 2021. e-Pub 2021. PMID: 32920733.
4. Ready K, Litton JK, Arun BK. Clinical application of breast cancer risk assessment models. Future Oncol 6(3):355-65, 2010. e-Pub 2010. PMID: 20222793.
5. Litton JK, Theriault RL. Breast cancer and pregnancy: Current concepts in diagnosis and treatment. Oncologist 15(12):1238-47, 2010. e-Pub 2010. PMID: 21147871.
6. Litton JK, Theriault RL, Gonzalez-Angulo AM. Breast cancer diagnosis during pregnancy. Women's Health (Lond Engl) 5(3):243-9, 2009. e-Pub 2009. PMID: 19392610.

Other Articles

1. Litton JK.

Editorials

1. Theriault RL, Litton JK. Pregnancy during or after breast cancer diagnosis; what do we know and what do we need to know?. J Clin Oncol, 2013.
2. Woodard TL, Litton JK. Fertility preservation in women with breast cancer: Challenges and opportunities. Oncology (Williston Park) 27(6):544, 546, 2013. PMID: 23909068.
3. Litton JK. The Oncologist 17(6):744-6, 4/2012. PMID: 22531361. Is age still the deciding factor?, 2012.

Abstracts

1. Litton JK, Yam C, Patel M, Sun J, Adrada BE, Raghavendra AS, Mouabbi JA, Iheme AN, Saleem S, Moscol G, Wright MD, Buzdar A, Murthy RK, Korkut A, Valero V, Tripathy D, Moseley TW, Wei P, Huo L, Rauch GM. Early on-treatment (on-Rx) tumor volume reduction (TVR) to predict response to the KEYNOTE-522 (KN-522) regimen in early stage triple negative breast cancer (TNBC), 2025. e-Pub 2025.
2. Litton JK. Neoadjuvant talazoparib (TALA) for operable breast cancer pts with BRCA mutation, 2023. e-Pub 2023.
3. Mohamed RM, Panthi B, Adrada B, Candelaria R, Guirguis MS, Yang W, Boge M, Patel M, Elshafeey N, Pashapoor S, Zhou Z, Son JB, Hwang K, Le-Petross H, Leung J, Scoggins ME, Whitman GJ, Xu Z, Lane DL, Moseley T, Perez F, White J, Chen H, Sun J, Wei P, Litton JK, Valero V, Yam C, Pagel M, Ma J, Rauch G. A Pre-operative Dynamic Contrast Enhanced MRI-Based Radiomics Models as Predictors of Treatment Response after Neoadjuvant Systemic Therapy in Triple Negative Breast Cancer Patients, 2022. e-Pub 2022.
4. Litton JK. Discussant for the POSITIVE Trial - Pregnancy after Breast Cancer, 2022. e-Pub 2022.
5. Damodaran S, Liu D, Schwartz J, Valero V, Ramirez D, Saleem S, Ueno NT, Ibrahim NK, Karuturi MS, Murthy RK, Moulder S, Litton JK. A phase Ib trial of bintrafusp alfa and eribulin in patients with metastatic triple negative breast cancer (TNBC), 2022. e-Pub 2022.
6. Panthi B, Mohamed RM, Adrada B, Candelaria R, Guirguis MS, Yang W, Boge M, Patel M, Elshafeey N, Pashapoor S, Zhou Z, Son JB, Hwang K, Le-Petross H, Leung J, Scoggins ME, Whitman GJ, Xu Z, Lane DL, Moseley T, Perez F, White J, Ravenberg E, Clayborn A, Pagel M, Chen H, Sun J, Wei P, Thompson AM, Moulder S, Korkut A, Huo L, Hunt KK, Litton JK, Valero V, Tripathy D, Yam C, Ma J, Rauch G. Longitudinal DCE-MRI Radiomic Models for Early Prediction of Response to Neoadjuvant Systemic Therapy (NAST) in Triple Negative Breast Cancer (TNBC) Patients, 2022. e-Pub 2022.
7. Mohamed RM, Panthi B, Adrada B, Candelaria R, Guirguis MS, Yang W, Boge M, Patel M, Elshafeey N, Pashapoor S, Zhou Z, Son JB, Hwang K, Le-Petross H, Leung J, Scoggins ME, Whitman GJ, Xu Z, Lane DL, Moseley T, Perez F, White J, Ravenberg E, Clayborn A, Pagel M, Chen H, Sun J, Wei P, Thompson AM, Moulder S, Korkut A, Huo L, Hunt KK, Litton JK, Valero V, Tripathy D, Yam C, Ma J, Rauch G. Multi-Parametric MRI-Based Radiomics Models from Tumor and Peritumoral Regions as Potential Predictors of Treatment Response to Neoadjuvant Systemic Therapy in Triple Negative Breast Cancer Patients, 2022. e-Pub 2022.
8. Guirguis MS, Adrada B, Patel M, Perez F, Candelaria R, Yang W, Sun J, Mohamed RM, Boge M, Le-Petross H, Leung J, Whitman GJ, Lane DL, Scoggins ME, Moseley T, Musall B, Pashapoor S, Wei P, Son JB, Hwang K, Panthi B, Pagel M, Huo L, Hunt KK, Ravenberg E, Thompson AM, Litton JK, Valero V, Tripathy D, Moulder S, Yam C, Ma J, Rauch G. DCE-MRI for early prediction of excellent response versus chemoresistance in triple negative breast cancer, 2022. e-Pub 2022.
9. Aftimos PG, Oliveira M, Punie K, Boni V, Hamilton EP, Gucalp A, Shah PD, de Miguel MJ, Sharma P, Bauman L, Campeau E, Attwell S, Snyder M, Norek K, Johnson E, Silverman MH, Lakhotia S, Domchek SM, Litton JK, Robson ME. A phase 1b/2 study of the BET inhibitor ZEN-3694 in combination with talazoparib for treatment of patients with TNBC without gBRCA1/2 mutations, 2022. e-Pub 2022.
10. Abuhadra N, Chang C, Yam C, White JB, Ravenberg E, Lim B, Ueno NT, Litton JK, Arun B, Damodaran S, Murthy RK, Ibrahim NK, Hortobagyi GN, Valero V, Tripathy D, Thompson AM, Mittendorf EA, Huo L, Moulder SL, Jenq RR. The impact of gut microbial composition on response to neoadjuvant chemotherapy (NACT) in early-stage triple negative breast cancer (TNBC), 2021. e-Pub 2021.
11. Ettl J, Rugo HS, Hurvitz SA, Martin M, Roche H, Lee K, Goodwin A, Usari T, Lanzalone S, Guenzel C, Blum JL, Litton JK. Characterization of long-term responders following treatment with talazoparib (TALA) or physician’s choice of chemotherapy (PCT) in the phase 3 embraca trial, 2021. e-Pub 2021.
12. Litton JK, Ettl J, Hurvitz SA, Martin M, Roche H, Lee K, Goodwin A, Usari T, Lanzalone S, Guenzel C, Blum JL, Rugo HS. Clinical outcomes in patients (pts) with a history of central nervous system (CNS) metastases receiving talazoparib (TALA) or physician’s choice of chemotherapy (PCT) in the phase 3 EMBRACA trial, 2021. e-Pub 2021.
13. Yam C, Mittendorf EA, Sun R, Huo L, Damodaran S, Rauch GM, Candelaria RP, Adrada BE, Seth S, Symmans WF, Murthy RK, White JB, Ravenberg E, Clayborn A, Prabhakaran S, Valero V, Thompson AM, Tripathy D, Moulder SL, Litton JK. Neoadjuvant atezolizumab (atezo) and nab-paclitaxel (nab-p) in patients (pts) with triple-negative breast cancer (TNBC) with suboptimal clinical response to doxorubicin and cyclophosphamide (AC), 2021. e-Pub 2021.
14. Litton JK, Beck JT, Jones JM, Andersen J, Blum JL, Mina LA, Brig R, Danso MA, Yuan Y, Abbattista A, Noonan K, Chakrabarti J, Czibere A, Symmans WF, Telli ML. Neoadjuvant talazoparib in patients with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Results of a phase 2 study, 2021. e-Pub 2021.
15. Telli ML, Litton JK, Beck JT, Jones JM, Andersen J, Mina LA, Brig R, Danso MA, Yuan Y, Symmans WF, Abbattista A, Noonan K, Mata M, Laird D, Blum JL. Neoadjuvant talazoparib (TALA) in patients (pts) with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Exploration of tumor BRCA mutational status and zygosity and overall mutational landscape in a phase 2 study, 2021. e-Pub 2021.
16. Seth S, Crespo J, Huo L, Thompson AM, Mittendorf EA, Hess KR, Litton JK, Rauch GM, Adrada BE, Damodaran S, Candelaria RP, Arun B, Yang WT, Santiago L, Murthy RK, Sahin AA, Symmans WF, Moulder SL, Ueno NT, Lim B. Evaluation of predictive biomarkers for AR therapy and to identify the LAR subtype of TNBC, 2019. e-Pub 2019.
17. Diab S, Rugo HS, Mina LA, Puhalla S, Mahtani RL, Henry NL, Denduluri N, Yardley DA, Wang Y, Arruda LS, Tudor IC, Gauthier ER, Czibere AG, Litton JK, Hurvitz SA. Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study, 2019. e-Pub 2019.
18. Campf J, Clifton GT, Hale DF, Vreeland TJ, Hickerson A, Holmes JP, Litton JK, Murthy RK, Lukas JJ, Mittendorf EA, Peoples GE. Immunologic responses in triple-negative breast cancer patients in a randomized phase IIb trial of nelipepimut-S plus trastuzumab versus trastuzumab alone to prevent recurrence, 2019. e-Pub 2019.
19. Seth S, Huo L, Rauch GM, Adrada BE, Piwnica-Worms H, Thompson AM, Mittendorf EA, Litton JK, Symmans WF, Draetta GF, Al F, Moulder SL, Chang J. Delineating longitudinal patterns of response to neoadjuvant systemic therapy (NAST) in triple-negative breast cancer (TNBC): Profiling results from a randomized, TNBC enrolling trial to confirm molecular profiling improves survival (ARTEMIS; NCT02276443), 2019. e-Pub 2019.
20. Abuhadra N, Hess KR, Litton JK, Rauch GM, Thompson AM, Lim B, Adrada BE, Mittendorf EA, Damodaran S, Candelaria RP, Arun B, Yang WT, Ueno NT, Santiago L, Murthy RK, Ibrahim NK, Sahin AA, Symmans WF, Moulder SL, Huo L. Beyond TILs: Predictors of pathologic complete response (pCR) in triple-negative breast cancer (TNBC) patients with moderate tumor-infiltrating lymphocytes (TIL) receiving neoadjuvant therapy, 2019. e-Pub 2019.
21. Ettl J, Hurvitz SA, Rugo HS, Lee KH, Mina LA, Woodward NE, Yerushalmi R, Diab S, Martin M, Tudor IC, Czibere AG, Gauthier ER, Litton JK, Goncalves A. Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial, 2019. e-Pub 2019.
22. Hobbs E, Yang F, Kumar T, Contreras A, Cuentas ERP, Garber H, Scoggins M, Adrada BE, Whitman GJ, Arun B, Mittendorf EA, Litton JK. Tumor immune microenvironment (TiME) changes by multiplex IF staining in a pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a BRCA mutation, 2019. e-Pub 2019.
23. Litton JK. A phase 2, open-label, single-arm, multi-center study of talazoparib for neoadjuvant treatment of germline BRCA1/2 mutation patients (pts) with early stage triple-negative breast cancer (TNBC), 2019. e-Pub 2019.
24. Litton J, Symmans F, Gogineni K, Saltzman M, Telli ML, Usha L, Chakrabarti J, Tudor IC, Quek RG, Czibere A. A phase 2, open-label, single-arm, multi-center study of talazoparib for neoadjuvant treatment of germline BRCA1/2 mutation patients with early-stage triple-negative breast cancer (TNBC), 2018. e-Pub 2018.
25. Yam C, Raghavendra A, Hess KR, Adrada BE, Candelaria RP, Damodaran S, Gilcrease MZ, Helgason T, Hortobagyi GN, Huo L, Layman RM, Lim B, Litton JK, Mittendorf EA, Murthy RK, Piwnica-Worms H, Rauch GM, Santiago L, Symmans F, Thompson AM, Tripathy D, Ueno NT, Valero V, Barcenas CH, Moulder SL, Yang W. Impact of serial biopsies in triple-negative breast cancer patients receiving neoadjuvant systemic therapy, 2018. e-Pub 2018.
26. Damodaran S, Meric-Bernstam F, Hess KR, Litton JK, Raymond V, Lanman R, Ueno NT, Hamilton S, Wistuba II, Valero V, Moulder SL, Tripathy D. INTERACT- INTegrated Evaluation of Resistance and Actionability using Circulating Tumor DNA in hormone receptor (HR) positive metastatic breast cancers (MBC), 2018. e-Pub 2018.
27. Murthy RK, Raghavendra AS, Hess KR, Barcenas CH, Lim B, Moulder SL, Giordano SH, Mittendorf EA, Thompson A, Ueno NT, Valero V, Litton JK, Tripathy D, Chavez-Macgregor M. 3-year relapse-free survival of stage II-III HER2-neu positive breast cancer treated with pertuzumab and trastuzumab-containing neoadjuvant therapy compared to trastuzumab-containing therapy, 2018. e-Pub 2018.
28. Mina L, K-H L, Gonçalves A, Woodward N, Hurvitz SA, Diab S, Yerushalmi R, Goodwin A, Moreira Costa Zorzetto M, S-B K, Czibere A, Tudor IC, Gauthier E, Litton JK, Banner EJ. EMBRACA: Efficacy and safety of talazoparib or physician's choice of therapy in patients with advanced breast cancer and a germline BRCA1/2 mutation: A regional analysis, 2018. e-Pub 2018.
29. Clifton GT, Kemp Bohan PM, Hale DF, Myers JW, Brown TA, Holmes JP, Vreeland TJ, Litton JK, Murthy RK, Mittendorf EA, Peoples GE. Subgroups analysis of a multicenter, prospective, randomized, blinded phase 2b trial of trastuzumab + nelipeptimut-S (NeuVax) vs trastuzumab for prevention of recurrence in breast cancer patients, 2018. e-Pub 2018.
30. Yam C, Hess KR, Litton JK, Yang WT, Santiago L, Candelaria RP, Mittendorf EA, Murthy RK, Damodaran S, Helgason T, Huo L, Thompson AM, Barton M, Huang ML, Arribas EM, Lane DL, Rauch GM, Adrada BE, Gilcrease MZ, Moulder SL. Impact of metaplastic histology (MpBC) in triple-negative breast cancer (TNBC) patients (pts) receiving neoadjuvant systemic therapy (NAST), 2018. e-Pub 2018.
31. Litton JK, Scoggins M, Hess KR, Adrada B, Barcenas CH, Murthy RK, Damodaran S, DeSnyder SM, Brewster AM, Thompson AM, Whitman GJ, Ibrahim NK, Moulder SL, Schwartz-Gomez J, Mittendorf EA, Arun B. Neoadjuvant talazoparib (TALA) for operable breast cancer patients with a BRCA mutation (BRCA+), 2018. e-Pub 2018.
32. Eiermann W, Rugo HS, Diab S, Ettl J, Hurvitz SA, Goncalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roche HH, Im YH, Markova D, Tudor IC, Blum JL, Hannah AL, Litton JK. Analysis of germline BRCA1/2 mutated (gBRCAmut) hormone receptor-positive (HR+) and triple negative breast cancer (TNBC) treated with talazoparib (TALA), 2018. e-Pub 2018.
33. Westin SN, Litton JK, Williams RA, Shepherd CJ, Brugger W, Pease EJ, Soliman PT, Frumovitz MM, Levenback CF, Sood A, Meyer L, Moulder SL, Valero V, Saleem S, Rodriguez AM, Cyriac A, Engerman L, Samuel C, Mills GB, Coleman RL. Phase I trial of olaparib (PARP inhibitor) and vistusertib (mTORC1/2 inhibitor) in recurrent endometrial, ovarian and triple negative breast cancer, 2018. e-Pub 2018.
34. Clifton K, Kimmel J, Litton JK, Tripathy D, Ms K. Examining progression free survival (PFS), overall survival (OS), and toxicities of palbociclib in a geriatric population, 2018. e-Pub 2018.
35. Yap TA, Burris HA, Kummar S, Falchook GS, Pachynski RK, LoRusso P, Tykodi SS, Gibney GT, Gainor JF, Rahma OE, Seiwert TY, Meric-Bernstam F, Blum Murphy MA, Litton JK, Hooper EMD Hirsch HA, Harvey C, Clancy M, McClure T, Callahan MK. ICONIC: Biologic and clinical activity of first in class ICOS against antibody JTX-2011 +/- nivolumab (nivo) in patients (pts) with advanced cancers, 2018. e-Pub 2018.
36. Rugo HS, Ettl J, Woodward NE, Hurvitz SA, Goncalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roche HH, Im YH, Markova D, Tudor IC, Eiermann W, Blum JL, Hannah AL, Litton JK. EMBRACA: Efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation, 2018. e-Pub 2018.
37. Moulder SL, Hess KR, Candelaria RP, Rauch GM, Santiago L, Adrada B, Yang WT, Gilcrease MZ, Huo L, Stauder MC, Arun B, Layman RM, Murth RK, Damodaran S, Ueno NT, Thompson AM, Lim B, Mittendorf EA, Litton JK, Symmans WF. Precision neoadjuvant therapy (P-NAT): A planned interim analysis of a randomized, TNBC enrolling trial to confirm molecular profiling improves survival (ARTEMIS), 2018. e-Pub 2018.
38. Rauch GM, Zhu H, Li H, Adrada BE, Santiago L, Candelaria RP, Wang H, Leung J, Litton J, Wu Y, Murthy R, Mittendorf EA, Yang W. Association of quantitative MRI features with tumor infiltrating lymphocytes and treatment response prediction in HER2 positive subtype of breast cancer, 2017. e-Pub 2017.
39. Parkes AM, Clifton KK, Al Awadhi A, Oke OC, Warneke CL, Litton JK, Hortobagyi GN. Tumor subtype concordance between breast and bone biopsies in bone only metastasis patients, 2017. e-Pub 2017.
40. Yam C, Santiago L, Candelaria RP, Adrada BE, Rauch GM, Hess KR, Litton JK, Piwnica-Worms H, Mittendorf EA, Ueno NT, Lim B, Murthy RK, Damodaran S, Helgason T, Huo L, Thompson AM, Gilcrease MZ, Symmans WF, Moulder SL, Yang. Risk of needle-track seeding with serial ultrasound guided biopsies in triple negative breast cancer, 2017. e-Pub 2017.
41. Litton J, Rugo HS, Ettl J, Hurvitz S, a G, Lee KY, l F, r Y, Mina LA, Martin M, Roche H, Im YH, Quek RGW, Tudor IC, Hannah AL, Eirmann W, Blum JL. EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germline BRCA mutation, 2017. e-Pub 2017.
42. Yam C, Huo L, Hess KR, Litton JK, Yang W, Piwnica-Worms H, Mittendorf EA, Ueno NT, Lim B, Murthy RK, Damodaran S, Helgason T, Thompson AM, Santiago L, Candelaria RP, Rauch GM, Adrada BE, Symmans WF, Gilcrease MZ, Moulder SL. Androgen receptor positivity is associated with nodal disease in triple negative breast cancer, 2017. e-Pub 2017.
43. Ross JL, Woodson AH, Gutierrez Barrera AM, Litton JK. Multi-gene panel testing results in patients with multiple breast cancer primaries, 2017. e-Pub 2017.
44. Yam C, Gutierrez Barrera A, Huang D, Lin X, Litton JK, Arun B. Implications of somatic TP53 and PIK3CA mutations in patients with metastatic breast cancer who underwent germline BRCA testing, 2017. e-Pub 2017.
45. Rauch GM, Li H, Zhu H, Adrada BE, Santiago L, Candelaria RP, Wang H, Leung J, Thompson A, Litton J, Wu Y, Lim B, Moulder S, Mittendorf EA, Yang W. Quantitative MRI features analysis for differentiation of triple negative and HER2 positive subtypes of breast cancer, 2017. e-Pub 2017.
46. Echeverria GV, Cai S, Tu Y, McCoy A, Lau R, Redwood A, Rauch G, Adrada B, Candelaria R, Santiago L, Thompson A, Litton J, Moulder S, Symmans F, Chang JT, Piwnica-Worms H. A molecularly annotated collection of breast cancer patient-derived xenograft models aligned with ongoing clinical trials built from fine needle aspiration samples throughout neoadjuvant treatment, 2017. e-Pub 2017.
47. Clifton KK, Kimmel J, Yi M, Chad B, Litton J, Debu T, Meghan K. The impact of dose delays and reductions on toxicity and progression free survival (PFS) in patients receiving palbociclib, 2017. e-Pub 2017.
48. Yam C, Hess KR, Litton JK, Yang WT, Piwnica-Worms H, Mittendorf EA, Ueno NT, Lim B, Murthy RK, Damodaran SK, Helgason T, Huo L Thompson AM, Gilcrease M, Santiago L, Candelaria RP, Rauch G, Adrada B, Symmans WF, Moulder SL. A randomized, triple negative breast cancer enrolling trial to confirm molecular profiling improves survival (ARTEMIS), 2017. e-Pub 2017.
49. Peace KM, Mittendorf EA, Perez SA, Tzonis P, Pistamaltzian NF, Anastasopoulou EA, Vreeland TJ, Hale DF, Clifton GT, Litton JK, von Hofe E, Ardavanis A, Papamichail M, Peoples GE. Subgroup efficacy evaluation of the AE37 HER2 vaccine in breast cancer patients in the adjuvant setting, 2017. e-Pub 2017.
50. Clifton K, Barrera AG, Ma J, Bassett RL, Litton JK, Arun B. Adjuvant or neoadjuvant chemotherapy in early stage triple negative breast cancer (TNBC) comparison of outcomes in both BRCA positive and BRCA negative patients, 2017. e-Pub 2017.
51. Oke O, Warneke CL, Chavez-Mac Gregor M, Milbourne A, Litton JK. Outcomes related to delayed initiation of anti-HER2 therapy in pregnant HER2 positive breast cancer patients, 2017. e-Pub 2017.
52. Dumbrava EEI, Brusco L, Daniels MS, Wathoo C, Shaw KR, Lu KH, Zheng X, Strong LC, Litton JK, Arun B, Eterovic AK, Routbort M, Piha-Paul SA, Subbiah V, Hong DS, Kopetz S, Mendelsohn J, Mills GB, Chen K, Meric-Bernstam F. Prevalence of incidental germline pathogenic (PV) and likely pathogenic (LPV) variants in hereditary cancer-related genes identified in matched tumor/normal sequencing of advanced solid tumors, 2017. e-Pub 2017.
53. Parkes A, Clifton K, Awadhi AA, Oke O, Warneke CL, Litton JK, Hortobagyi GN. Characterization of bone only metastasis (BOM) patients (pts) with respect to tumor subtypes (TS), 2017. e-Pub 2017.
54. Dumbrava EAI, Brusco L, Daniels MS, Wathoo C, Shaw KR, Lu KH, Zheng X, Strong LC, Litton JK, Arun B, Eterovic AK, Piha-Paul SA, Subbiah V, Hong DS, Woodman SE, Mendelsohn J, Yap TA, Mills GB Chen K, Meric-Bernstam F. Pathogenic variants in DNA damage response (DDR) genes in patients with advanced solid tumors, 2017. e-Pub 2017.
55. Litton JK, Scoggins M, Whitman GJ, Barcenas CH, Moulder SL, Murthy RK, Abouharb S, Adrada B, Helgason T, Schwartz-Gomez J, Mittendorf EA, Thompson AM, Arun B. A feasibility study of neoadjuvant talazoparib for early-stage breast cancer patients with a germline BRCA pathogenic variant: NCT02282345, 2017. e-Pub 2017.
56. Arun B, Elsayegh N, Lin HY, Clifton K, Gutierrez-Barrera AM, Litton JK, Albarracin CT. Breast cancer phenotype in patients with hereditary gene mutations other than BRCA1 and BRCA2, 2017. e-Pub 2017.
57. Scoggins M, Dogan B, Ma J, Wei W, Song JB, Candelaria RP, Litton JK, Arun B. Short breast MRI screening trial in women at high-risk for breast cancer, 2017. e-Pub 2017.
58. Murthy RK, Fujii T, Hess KR, Raghavendra AS, Lim B, Barcenas CH, Zhang HA, Chavez-Mac Gregor M, Mittendorf EA, Litton JK, Giordano SH, Thompson AM, Valero V, Tripathy D, Ueno NT. Effect of neoadjuvant pertuzumab-containing regimens on pathologic complete response rates in stage II-III HER2-neu positive breast cancer: A retrospective, single institutional experience, 2017. e-Pub 2017.
59. Litton JK, Scoggins M, Ramirez DL, Murthy RK, Whitman GJ, Hess KR, Adrada BE, Moulder SL, Barcenas CH, Valero V, Booser D, Schwartz Gomez J, Mills GB, Piwnica-Worms H, Arun BK. A pilot study of neoadjuvant talozoparib for early-stage breast cancer patients with a BRCA mutation, 2016. e-Pub 2016.
60. Fujii T, Kogawa T, Dong W, Litton JK, Moulder SL, Tripathy D, Hunt K, Iwamoto T, Pusztai L, Lim B, Shen Y, Ueno NT. New threshold of ER positivity in early stage HER2- breast cancer, 2016. e-Pub 2016.
61. Rugo HS, Seneviratne L, Beck JT, Glaspy JA, Peguero JA, Pluard TJ, Dhillon N, Hwang LC, Nangia CS, Mayer IA, Meiller TF, Chambers MS, Warsi G, Sweetman RW, Sabo JR, Litton JK. Prevention of everolimus/exemestane (EVE/EXE) stomatitis in postmenopausal (PM) women with hormone receptor-positive (HR+) metastatic breast cancer (MBC) using a dexamethasone-based mouthwash (MW): Results of the SWISH trial, 2016. e-Pub 2016.
62. Muse KI, Bednar E, Emborgo TS, Oakley HD, Litton JK, Peterson SK, Lu KH, Arun B. Universal BRCA testing of TNBC and HGSOC and active family outreach to increase identification of at-risk relatives for cascade testing, 2016. e-Pub 2016.
63. Emborgo T, Muse KI, Bednar E, Oakley HD, Litton J, Lu KH, Arun BK. Universal BRCA testing and family outreach for women with triple negative breast cancer, 2015. e-Pub 2015.
64. Litton JK, Blum JL, Y-H I, Martin M, Mina L, Roché H, Visco F, Yang X, Lokker NA, Lounsbury DL, Eiermann W. EMBRACA: A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) versus physician's choice in BRCA mutation subjects with locally advanced and/or metastatic breast cancer, 2015. e-Pub 2015.
65. Mitri ZI, Ueno NT, Yang W, Valero V, Litton JK, Murthy RK, Ibrahim NK, Arun BK, Mittendorf EA, Hunt KK, Meric-Bernstam F, Thompson A, Piwnica-Worms H, Tripathy D, Symmans F, Moulder-Thompson S. Women's triple-negative, first-line treatment: Improving outcomes in triple-negative breast cancer using molecular triaging and diagnostic imaging to guide neoadjuvant therapy, 2015. e-Pub 2015.
66. Greene JM, Schneble EJ, Perez S, Murray JL, Berry JS, Trappey AF, Hale DF, Vreeland TJ, Clifton GT, Ardavanis A, Litton JK, Shumway NM, Papamichail M, Peoples GE, Mittendorf EA. Final pre-specified analysis of the phase II trial of the GP2+GM-CSF peptide vaccine in high risk breast cancer patients to prevent recurrence, 2015. e-Pub 2015.
67. Alvarez RH, Koenig KB, Ensor JE, Ibrahim NK, Chavez-MacGregor M, Litton JK, Schwartz Gomez JK, Cyriac A, Krishnamurthy S, Caudle AS, Shaitelman SF, Whitman GJ, Booser DJ, Reuben JM, Valero V. A randomized phase II neoadjuvant (NACT) study of sequential eribulin followed by FAC/FEC-regimen compared to sequential paclitaxel followed by FAC/FEC-regimen in patients (pts) with operable breast cancer not overexpressing HER-2, 2015. e-Pub 2015.
68. Basho RK, Gilcrease M, Murthy RK, Helgason T, Booser DJ, Karp DD, Meric-Bernstam F, Wheler JJ, Valero V, Albarracin C, Litton J, Chavez-MacGregor M, Ibrahim NK, Murray JL, Koenig KB, Hong D, Subbiah V, Kurzrock R, Janku F, Moulder S. Targeting the PI3K/AKT/mTOR pathway for the treatment of mesenchymal triple-negative breast cancer (TNBC): Evidence of efficacy and proof of concept from a phase I trial with dose expansion of mTOR inhibition in combination with liposomal doxorubicin and bevacizumab, 2015. e-Pub 2015.
69. Litton JK, Blum JL, Y-H I, Martin M, Mina L, Roché H, Visco F, Yang X, Lokker NA, Lounsbury DL, Eiermann W. EMBRACA: A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) versus physician's choice in BRCA mutation subjects with locally advanced and/or metastatic breast cancer, 2015. e-Pub 2015.
70. Fujii T, Kogawa T, Dong W, Moulder S, Litton JK, Tripathy D, Lim B, Shen Y, Ueno NT. Association between quantitative values of estrogen receptor expression level and pathological complete response in human epidermal growth factor 2-negative breast cancer: Should the clinical definition of triple-negative breast cancer be redefined?, 2015. e-Pub 2015.
71. Moulder SL, Ueno NT, Yang WT, Ensor J, Valero V, Litton JK, Murthy RK, Ibrahim NK, Arun B, Mittendorf EA, Hunt K, Meric-Bernstam F, Thompson AM, Piwnica-Worms H, Tripathy D, Symmans WF. Women’s triple-negative, first-line treatment: Improving outcomes in triple-negative breast cancer (TNBC) using molecular triaging and diagnostic imaging to guide neoadjuvant therapy (NACT), 2015. e-Pub 2015.
72. Basho RK, Gagliato DD, Ueno NT, Alvarez RH, Wathoo C, Chen H, Wei C, Sahin AA, Roy-Chowdhuri S, Moulder SL, Chavez-Mac Gregor M, Litton JK, Valero V, Luthra R, Shaw KR, Mendelsohn J, Mills GB, Tripathy D, Meric-Bernstam F. Clinical outcomes based on multigene profiling in metastatic breast cancer patients, 2015. e-Pub 2015.
73. Litton JK, Blum JL, Y-H I, Martin M, Mina LA, Roche HH, Rugo HS, Visco F, Zhang C, Lokker NA, Lounsbury DL, Eiermann W. A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA), 2015. e-Pub 2015.
74. Ardic C, Gutierrez-Barrera AM, Elsayegh N, Song J, Profato J, Litton JK, Giordano SH, Tripathy D, Arun B. Predictors of BRCA mutation in male breast cancer, 2015. e-Pub 2015.
75. Vila J, Bassett RL, Mittendorf EA, Bedrosian I, Shaitelman SF, Stauder MC, Chavez-Mac Gregor M, Litton JK, Yang WT, Huo L, Kuerer HM, Hunt K, Caudle AS. A nomogram to predict axillary response to neoadjuvant chemotherapy in clinically node positive breast patients, 2015. e-Pub 2015.
76. Fujii T, Kogawa T, Wei C, Fouad TM, Harano K, Park YS, Lim B, Tripathy D, Ueno NT, Litton JK. Association of body mass index with survival outcome in three breast cancer subtypes, 2015. e-Pub 2015.
77. Meric-Bernstam F, Brusco L, Daniels MS, Strong LC, Shaw KR, Lu, KH, QU Y, Lara-Guerra H, Litton JK, Zhao H, Eterovic AK, Arun B, Routbort M, Janku F, Davies MA, Kopetz S, Mendelsohn J, Mills GB, Chen K. Prevalence of incidental actionable germline mutations in 1,000 advanced cancer patients on a prospective somatic genomic profiling program, 2015. e-Pub 2015.
78. IIsaacs C, Ozguroglu M, Jerusalem G, Xu B, Láng I, O'Regan R, White M, Fasolo A, Litton J, Toi M, Shen K, Andre F, Vuylsteke P, Zhang Y, Zhang J, Taran T, Wilks S. BOLERO-3: Quality-of-life maintained in patients with metastatic breast cancer treated with everolimus plus trastuzumab plus vinorelbine, 2014. e-Pub 2014.
79. Murthy RK, Schover LR, Theriault RL, Valero V, Woodard TL, Hodge S, Litton JK. Women with pregnancy-associated early breast cancer achieve improved emotional well-being as a result of their cancer experience, 2014. e-Pub 2014.
80. Kogawa T, Fouad TM, Wei C, El-Zein RA, Masuda H, Chavez-Mac-Gregor M, Melhem-Bertrandt A, Litton JK, Brewster AM, Alvarez RH, Hortobagyi GN, Vicente V, Ueno NT, Theriault RL. Association between body mass index change during neoadjuvant chemotherapy and pathologic complete response and overall survival in patients with inflammatory breast cancer or locally advanced non-inflammatory breast cancer, 2014. e-Pub 2014.
81. Chavez-Mac Gregor M, Lei X, Litton JK, Melhem-Bertrand A, Giordano SH, Masuda H, Ueno N, Gabriel HN, Valero V. Statin use and outcome among breast cancer patients treated with neoadjuvant systemic chemotherapy, 2014. e-Pub 2014.
82. Elsayegh N, Gutierrez-Barrera A, Baum G, Muse K, Jackson M, Woodson A, Jessica P, Kuerer H, Litton J, Arun B. Factors associated with prophylactic mastectomy among BRCA-positive patients with no personal history of breast cancer, 2014. e-Pub 2014.
83. Rugo HS, Chambers MS, Litton J, Mayer I, Rogerio J, Demars L, Geronimo J, Warsi G, Meiller TF. Phase 2, single arm study of a steroid-based mouthwash to prevent stomatitis in women with hormone receptor–positive advanced breast cancer treated with everolimus plus exemestane, 2014. e-Pub 2014.
84. Schneble EJ, Perez SA, Murray JL, Berry JS, Trappey AF, Vreeland TJ, Hale DF, Greene JM, Clifton GT, Ardavanis A, Litton JK, Ponniah S, Shumway NM, Papamichail M, Peoples GE, Mittendorf EA, Medical Center SAM, Antonio S, TX, Immunology C, Center I, Cancer Hospital SS, Athens, Greece, Cancer Center TUOTMA, Houston, TX, Anticancer Hospital SS, Athens, Greece, Development Program CV, Cancer Institute USM, USUHS, Bethesda, MD, Immunology C, Center I, Athens, Greece, Medical Center SAM, Houston FS, TX. Primary analysis of the prospective, randomized, phase II trial of GP2+GM-CSF vaccine versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer patients, 2014. e-Pub 2014.
85. Sanford RA, Song J, Gutierrez-Barrera AM, Litton JK, Bedrosian I, Albarracin CT, Valero V, Arun B, Cancer Center TUOTMA, Houston, TX. Incidence of germline BRCA mutation in patients with ER-low positive/PR negative/HER-2 neu negative tumors, 2014. e-Pub 2014.
86. Elsayegh N, Lin HY, Gutierrez-Barrera AM, Profato J, Litton JK, Kuerer HM, Hortobagyi GN, Arun B, Cancer Center TUOTMA, Houston, TX, Cancer Center TUOTMA, HOUSTON, TX. Predictors that influence contralateral prophylactic mastectomy election among women with ductal carcinoma in situ who tested negative for a BRCA mutation, 2014. e-Pub 2014.
87. Schneble EJ, Perez SA, Murray JL, Berry JS, Trappey AF, Vreeland TJ, Hale DF, Greene JM, Clifton GT, Ardavanis A, Litton JK, Ponniah S, Shumway NM, Papamichail M, Peoples GE, Mittendorf EA, Medical Center SAM, Antonio S, TX, Immunology C, Center I, Cancer Hospital SS, Athens, Greece, Cancer Center TUOTMA, Houston, TX, Anticancer Hospital SS, Athens, Greece, Development Program CV, Cancer Institute USM, USUHS, Bethesda, MD, Immunology C, Center I, Athens, Greece, Medical Center SAM, Houston FS, TX. Primary analysis of the prospective, randomized, phase II trial of GP2+GM-CSF vaccine versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer patients, 2014. e-Pub 2014.
88. Sanford RA, Song J, Gutierrez-Barrera AM, Litton JK, Bedrosian I, Albarracin CT, Valero V, Arun B, Cancer Center TUOTMA, Houston, TX. Incidence of germline BRCA mutation in patients with ER-low positive/PR negative/HER-2 neu negative tumors, 2014. e-Pub 2014.
89. Mitri ZI, Jackson M, Garby C, Giordano SH, Hortobagyi GN, Singletary C, Hashmi SS, Arun B, Litton JK, Cancer Center TUOTMA, Houston, TX, Health B, Dallas, TX, Texas Health TUO, at Houston SC, Houston, TX. BRCAPRO 6.0 model validation in male patients presenting for BRCA testing, 2014. e-Pub 2014.
90. Dalal S, Hui D, Yeung SJ, Chisholm GB, Ihenacho IS, Ogunti R, De la Cruz M, Vidal M, Bedi D, Dev R, Bruera E, Cancer Center LJTUOTMA, Houston, TX. Association between visceral adiposity, BMI, and clinical outcomes in postmenopausal women with operable breast cancer, 2014. e-Pub 2014.
91. Rugo HS, Chambers MS, Litton JK, Mayer IA, Rogerio JW, DeMars LR, Geronimo J, Warsi G, Meiller TF, Medical Center UOCSF, Francisco S, CA, Cancer Center TUOTMA, Houston, TX, Center VC, University V, Medicine SO, Nashville, TN, Corporation NP, Hanover E, NJ, Center GC, Maryland UO, Baltimore, MD. Prevention of stomatitis in patients with hormone receptor–positive advanced breast cancer treated with everolimus plus exemestane: A phase II study of a steroid-based mouthwash, 2014. e-Pub 2014.
92. Murthy RK, Chen H, Wei S, Jackson M, Woodson AH, Litton JK, Arun B, Valero V, Barcenas CH, Cancer Center TUOTMA, Houston, TX. Genetic testing referral patterns and clinical outcomes among high-risk breast cancer survivors, 2014. e-Pub 2014.
93. Murthy RK, Schover LR, Theriault RL, Valero V, Woodard TL, Hodge S, Cancer Center LJUOTMA, Houston, TX. Women with pregnancy-associated early breast cancer achieve improved emotional well-being as a result of their cancer experience, 2013. e-Pub 2013.
94. Chavez-Mac Gregor M, Lei X, Litton JK, Melhem-Bertrand A, Giordano SH, Masuda H, Ueno N, Gabriel HN, Cancer Center VVUMA, Houston, TX. Statin use and outcome among breast cancer patients treated with neoadjuvant systemic chemotherapy, 2013. e-Pub 2013.
95. Rugo HS, Chambers MS, Litton J, Mayer I, Rogerio J, Demars L, Geronimo J, Warsi G, Cancer Center MTUHDFC, Francisco S, CA, Cancer Center TUOTMA, Houston, TX, University V, Nashville, TN, Corporation NP, Hanover E, NJ, Medical System UOM, Baltimore, MD. Phase 2, single arm study of a steroid-based mouthwash to prevent stomatitis in women with hormone receptor–positive advanced breast cancer treated with everolimus plus exemestane, 2013. e-Pub 2013.
96. Isaacs C, Ozguroglu M, Jerusalem G, Xu B, Láng I, O'Regan R, White M, Fasolo A, Litton J, Toi M, Shen K, Andre F, Vuylsteke P, Zhang Y, Zhang J, Taran T, Georgetown University WS, Washington, DC, University I, Faculty CM, Istanbul, Turkey, Liege CHU, Liege, Belgium, Medical Sciences CAO, Medical College PU, Beijing, China, of Oncology NI, Budapest, Hungary, Emory University WCIO, Atlanta, GA, Cancer Center SR, Milano, Italy, Cancer Center TUOTMA, Houston, TX, of Medicine RHSJTUS, City S, China, University K, Kyoto, Japan, Roussy IG, Villejuif, France, Sainte Elisabeth CEM, Namur, Belgium, Pharmaceuticals N, Hanover E, NJ, Sainte Elisabeth CEM, Namur, Belgium, South Texas CCCO, Antonio S, TX, Health M, Bentleigh E, Victoria, Australia. BOLERO-3: Quality-of-life maintained in patients with metastatic breast cancer treated with everolimus plus trastuzumab plus vinorelbine, 2013. e-Pub 2013.
97. Elsayegh N, Gutierrez-Barrera A, Baum G, Muse K, Jackson M, Woodson A, Jessica P, Kuerer H, Litton J, Cancer Center ABUOTMA, Houston, TX. Factors associated with prophylactic mastectomy among BRCA-positive patients with no personal history of breast cancer, 2013. e-Pub 2013.
98. Kogawa T, Fouad TM, Wei C, El-Zein RA, Masuda H, Chavez-Mac-Gregor M, Melhem-Bertrandt A, Litton JK, Brewster AM, Alvarez RH, Hortobagyi GN, Vicente V, Ueno NT, Cancer Center TRTUOTMA, Houston, TX. Association between body mass index change during neoadjuvant chemotherapy and pathologic complete response and overall survival in patients with inflammatory breast cancer or locally advanced non-inflammatory breast cancer, 2013. e-Pub 2013.
99. Parinyanitikul N, Lei X, Chavez-Mac Gregor M, Mittendorf EA, Litton JK, Woodward WA, Zhang H, Hortobagyi GN, Gonzalez-Angulo AM, Cancer Center TUOTMA, Houston, TX. Receptor status change from primary to residual breast cancer after neoadjuvant chemotherapy (NCT) and analysis of survival outcome, 2013. e-Pub 2013.
100. Yardley DA, Campone M, Lebrun F, Noguchi S, Pritchard KI, Burris HA, Beck JT, Ito Y, Bachelot T, Pistilli B, Melichar B, Petrakova K, Arena FP, Erdkamp F, Harb WA, Litton JK, Brechenmacher T, El-Hashimy M, Taran T, Gnant M, Research Institute SC, Nashville, TN, l'Ouest/René Gauducheau IDCD, Saint-Herblain, France, Bordet IJ, Brussels, Belgium, Breast DO, Surgery E, University O, Osaka, Japan, Cancer Centre SO, Toronto UO, Toronto, ON, Canada, Group HO, Fayetteville, AR, Hospital CI, Medical Oncology JFFCRB, Center BO, Tokyo, Japan, Bérard CL, Lyon, France, Macerata Hospital DOO, Macerata, Italy, Medical School PU, Hospital T, Olomouc, Republic C, Cancer Institute MM, Brno, Republic C, Associates AO, Success L, NY, Center OM, Sittard, Netherlands, Research HO, Lafayette, IN, Cancer Center TUOTMA, Houston, TX, Novartis Pharma SAS, Rueil-Malmaison, France, Pharmaceuticals N, Park F, NJ, Center CC, Surgery DO, of Vienna MU, Vienna, Austria. Characterization of patients who received prior chemotherapy for advanced breast cancer (ABC) in BOLERO-2, 2013. e-Pub 2013.
101. Patil R, Clifton GT, Litton JK, Shumway NM, Vreeland TJ, Berry JS, Trappey AF, Ponniah S, Peoples GE, Mittendorf EA, Medicine DO, Cancer Institute RP, Buffalo, NY, Community Hospital BA, Campbell F, KY, Cancer Center TUOTMA, Houston, TX, Medical Center SAM, Houston FS, TX, Medical Center BA, Antonio S, TX, Development Program CV, Cancer Institute USM, USUHS, Bethesda, MD, Surgery DO, Medical Center BA, Houston FS, TX. Safety and efficacy of the HER2-derived GP2 peptide vaccine in combination with trastuzumab for breast cancer patients in the adjuvant setting, 2013. e-Pub 2013.
102. Kelly CM, Beamish R, McCaffrey J, Smith M, Crown J, O'Connor M, McGee SF, O'Reilly S, Moylan EJ, Gonzalez-Angulo AM, Litton JK, Pusztai L, Kelly CM, Medical Oncology DO, Hospital CU, Cork, Ireland, University Hospital MM, Dublin, Ireland, Medical Oncology DO, University Hospital MM, Dublin, Ireland, Medical Oncology DO, University Hospital SV, Dublin, Ireland, Hospital WR, Waterford, Ireland, Cancer Center TUOTMA, Houston, TX, Center YC, Haven N, CT. A comparative analysis of distant recurrence risk assessments by Oncotype DX recurrence score alone and integrated with clinicopathologic factors in early-stage breast cancer, 2013. e-Pub 2013.
103. Campone M, Lebrun F, Noguchi S, Pritchard KI, Burris HA, Beck JT, Ito Y, Yardley DA, Bachelot TD, Pistilli B, Melichar B, Petrakova K, Arena FP, Erdkamp F, Harb WA, Litton JK, Panneerselvam A, El-Hashimy M, Taran T, Gnant M, Gauducheau CR, en Cancerologie CDR, Herblain NS, France, Institute JB, Brussels, Belgium, Breast DO, Surgery E, University O, Osaka, Japan, Centre OC, Sciences Centre SH, Toronto UO, Toronto, ON, Canada, Research Institute SC, Nashville, TN, Group HO, Fayetteville, AR, Hospital CI, Medical Oncology JFFCRB, Center BO, Tokyo, Japan, Research Institute SC, Oncology T, Nashville, TN, Bérard CL, Lyon, France, Macerata OD, Macerata, Italy, Medical School PU, Hospital T, Olomouc, Republic C, Cancer Institute MM, Brno, Republic C, Associates AO, Success L, NY, Center OM, Sittard, Netherlands, Research HO, Lafayette, IN, Cancer Center TUOTMA, Houston, TX, Corp NP, Park F, NJ, Corp NP, Hanover E, NJ, Center CC, of Vienna MU, Vienna, Austria. Characterization of patients who received prior chemotherapy for advanced breast cancer (ABC) in BOLERO-2, 2013. e-Pub 2013.
104. Afrough A, Lin H, Gutierrez-Barrera AM, Litton JK, Valero V, Arun B, Cancer Center TUOTMA, Houston, TX. Outcomes of HER2-positive nonmetastatic breast cancer patients with or without deleterious BRCA mutations after trastuzumab treatment, 2013. e-Pub 2013.
105. Woodson AH, Muse KI, Jackson M, Arun B, Litton JK. Impact of Breast Cancer and BRCA Mutations on Thoughts and Feelings of Future Pregnancies, 2012. e-Pub 2012.
106. Milbourne A, Sun CC, Fanale MA, Theriault RL, Rimes SA, Litton JK, Ramirez MM, Cancer Center UOTMDA, Houston, TX, of Medicine BS, Houston, TX. Pregnancy outcomes in women with cancer, 2012. e-Pub 2012.
107. Dallas NA, Yi M, Hunt K, Shah RR, Kuerer HM, Litton JK, Wu Y, Caudle AS, Meric-Bernstam F, Sahin AA, Mittendorf EA, Cancer Center UOTMDA, Houston, TX. Evaluation of the stage IB designation of the 7th edition of the AJCC staging system, 2012. e-Pub 2012.
108. Dawood SS, Dent RA, Gupta S, Litton JK, Mustafa R, Cortes J, Mittendorf EA, Gonzalez-Angulo AM, Buchholz TA, Hospital D, Dubai, Emirates UA, Centre Singapore NC, Singapore, Singapore, Hospital TM, Mumbai, India, Cancer Center UOTMDA, Houston, TX, Department MO, University Hospital VD, Barcelona, Spain. Impact of surgery and radiation of the primary among women with de novo stage IV breast cancer, 2012. e-Pub 2012.
109. Elsayegh N, Gutierrez-Barrera AM, Muse KI, Lin H, Turco DL, Litton JK, Kuerer HM, Arun B, Cancer Center UOTMDA, Houston, TX. Predictors of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ (DCIS) who underwent evaluation for BRCA genetic testing, 2012. e-Pub 2012.
110. Yennurajalingam S, Frisbee-Hume S, Delgado-Guay MO, Bull J, Phan AT, Tannir NM, Litton JK, Palmer JL, Reddy AS, Hui D, Dalal S, Massie L, Vadhan-Raj S, Reddy SK, Reuben JM, Bruera E, Cancer Center UOTMDA, Houston, TX, Hospice FS, Rock F, NC. Dexamethasone (DM) for cancer-related fatigue: A double-blinded, randomized, placebo-controlled trial, 2012. e-Pub 2012.
111. Chae YK, Brown EN, Lei X, Melhem-Bertrandt A, Giordano SH, Litton JK, Hortobagyi GN, Gonzalez-Angulo AM, Chavez-MacGregor M, Cancer Center UOTMDA, Houston, TX. ACE inhibitors and angiotensin receptor blockers use and breast cancer outcomes in patients treated with neoadjuvant systemic chemotherapy, 2012. e-Pub 2012.
112. Litton JK, Etzel CJ, Jackson MA, Muse KI, Turco D, Schover LR, Theriault RL, Mattair D, Lu KH, Hortobagyi GN, Arun BK. Breast cancer, BRCA mutations and attitudes regarding pregnancy and preimplantation genetic diagnosis, 2011. e-Pub 2011.
113. Muse KI, Elsayegh N Gutierrez-Barrera AM, Kuerer H, Valero V, Litton JK, Hortobagyi GN, Arun BK. Evaluation of BRCAPro Risk assessment model in patients with ductal carcinoma in situ, 2011. e-Pub 2011.
114. Turco DL, Elsayegh N, Litton JK Hortobagyi GN, Arun B. Testing women with invasive lobular breast cancer for BRCA mutations, 2011. e-Pub 2011.
115. Jackson M, Mattair D, Lin H, Gutierrez-Barrera AM, Elsayegh N, Litton JK, Hortobagyi GN, Arun B, Cancer Center UOTMDA, Houston, TX. Identifying genomic rearrangements in BRCA1 and BRCA2 in high-risk individuals for hereditary breast and ovarian cancer, 2011. e-Pub 2011.
116. Arun B, Biswas S, Tankhiwale N, Blackford AL, Gutierrez-Barrera AM, Litton JK, Hortobagyi GN, Amos CI, Parmigiani G, Cancer Center UOTMDA, Houston, TX, Science Center UONTH, Worth F, TX, of Medicine TJHUS, Baltimore, MD, Institute DC, Boston, MA. Assessing the added value of breast tumor markers in breast cancer genetic risk prediction model BRCAPRO, 2011. e-Pub 2011.
117. Gonzalez-Angulo AM, Green MC, Murray JL, Palla SL, Koenig KH, Brewster AM, Valero V, Ibrahim NK, Moulder SL, Litton JK, Crawford DJ, Flores PR, Dryden MJ, Symmans WF, Giordano SH, Pusztai L, Buzdar A, Mills GB, Hortobagyi GN, Meric-Bernstam F, Center M, Houston, TX, Cancer Center UOTMDA, Houston, TX, Cancer Therapeutics DOI, Cancer Center UOTMDA, Houston, TX. Open label, randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC (T-FEC) versus the combination of paclitaxel and RAD001 followed by FEC (TR-FEC) in women with triple receptor-negative breast cancer (TNBC), 2011. e-Pub 2011.
118. Dawood SS, Lei X, Litton JK, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM, Hospital D, Dubai, Emirates UA, Cancer Center UOTMDA, Houston, TX, Center M, Houston, TX. Effect of body mass index on survival outcome among women with early-stage, triple-negative breast cancer, 2011. e-Pub 2011.
119. Elsayegh N, Bayraktar S, Gutierrez-Barrera AM, Lin H, Kuerer HM, Muse KI, Ready K, Litton JK, Meric-Bernstam F, Hortobagyi GN, Arun B, Cancer Center UOTMDA, Houston, TX, Hospital JM, Miami UO, Miami, FL. Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ, 2011. e-Pub 2011.
120. Holland MG, McCampbell A, Litton JK, Theriault RL, Ramirez MM, at Houston UOTHSC, Houston, TX, Cancer Center UOTMDA, Houston, TX. Alterations in breast cancer resistance protein in human placentas exposed to chemotherapy, 2011. e-Pub 2011.
121. Lei X, Dawood SS, Litton JK, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM, Cancer Center UOTMDA, Houston, TX, Hospital D, Dubai, Emirates UA, Center M, Houston, TX. Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer, 2011. e-Pub 2011.
122. Chavez-MacGregor M, Lei X, Litton JK, Melhem A, Mittendorf EA, Meric-Bernstam F, Sahin AA, Valero V, Hortobagyi GN, Gonzalez-Angulo AM, Cancer Center UOTMDA, Houston, TX, Center M, Houston, TX. Predictors of recurrence among patients with breast cancer who achieved a pathologic complete response (pCR) after neoadjuvant systemic chemotherapy, 2011. e-Pub 2011.
123. Morrow PK, Broxson AC, Munsell M, Basen-Engquist K, Rosenblum CK, Nguyen LH, Schover LR, Hahn K, Litton JK, Hortobagyi GN, Cancer Center UOTMDA, Houston, TX. Long-term effects of the diagnosis and treatment of breast cancer upon young breast cancer survivors, 2011. e-Pub 2011.
124. Litton JK, Hodge S, Mattair D, Ramirez MM, Morrow PK, Gonzalez-Angulo AM, Barnett CM, Hortobagyi GN, Theriault RL. Outcomes of children exposed to chemotherapy in utero for breast cancer, 2011. e-Pub 2011.
125. Melhem-Bertrandt A, Reddy KJ, Gutierrez-Barrera AM, Litton JK, Strong LC, Olopade OI, Hortobagyi GN, Arun BK. Increased rate of HER2-positive breast cancers among women with germline TP53 mutations, 2010. e-Pub 2010.
126. Pusztai L, Moulder S, Litton JK, Valero V, Ueno N, Melhem-Bertrandt A, Morrow PK, Dotter K, Mattair D, Strauss L, Hortobagyi GN, Qi Y, Symmans WF. Prospective testing of three different gene-signatures for patient selection for dasatinib therapy in metastatic breast cancer, 2010. e-Pub 2010.
127. Arun BK, Gutierrez-Barrera AM, Akar U, Litton JK, Albarracin C, Gonzalez-Angulo AM, Hortobagyi GN. Outcome of triple negative breast cancer in patients with or without deleterious BRCA mutations, 2010. e-Pub 2010.
128. Chavez-MacGregor M, Brown EN, Lei X, Hsu L, Meric-Bernstam F, Litton JK, Mittendorf EA, Valero V, Hortobagyi GN, Gonzalez-Angulo AM. Bisphosphonates and pathologic complete response to neoadjuvant chemotherapy in patients with breast cancer, 2010. e-Pub 2010.
129. Litton JK, Warneke CL, Hahn KM, Palla SL, Kuerer HM, Perkins GH, Middleton LP, Gonzalez-Angulo AM, Hortobagyi GN, Theriault RL. Case-control analysis of patients treated with chemotherapy during pregnancy for breast cancer, 2010. e-Pub 2010.
130. Litton JK, Warneke CL, Hahn K, Palla SL, Kuerer HM, Perkins GH, Middleton LP, Gonzalez-Angulo AM, Hortobagyi GN, Theriault RL. Case-control analysis of patients (pts) treated with chemotherapy during pregnancy for breast cancer (BC), 2010. e-Pub 2010.
131. Gonzalez-Angulo AM, Chen H, Timms K, Litton JK, Potter J, Lanchbury JS, Arun B, Hortobagyi GN, Do K, Meric-Bernstam F, Cancer Center UOTMDA, Houston, TX, Genetics M, Inc, City SL, UT. Incidence and outcome of BRCA mutation carriers with triple receptor-negative breast cancer (TNBC), 2010. e-Pub 2010.
132. Gutierrez-Barrera AM, Turco DL, Alvarez RH, Litton JK, Valero V, Hortobagyi GN, Arun B, Cancer Center UOTMDA, Houston, TX. BRCA mutations in women with inflammatory breast cancer, 2010. e-Pub 2010.
133. Ready K, Gutierrez-Barrera AM, Litton JK, Lu KH, Hortobagyi GN, Arun B, Cancer Center UOTMDA, Houston, TX. Obesity, smoking, alcohol consumption, and risk of multiple primary breast cancers in BRCA1 and BRCA2 mutation carriers, 2010. e-Pub 2010.
134. Litton JK, Chen H, Mittendorf EA, Meric-Bernstam F, Chavez-MacGregor M, Woodward WA, Sahin A, Theriault RL, Hortobagyi GN, Gonzalez-Angulo AM. Outcomes differences in tumors < 1cm by age and breast cancer subtype, 2010. e-Pub 2010.
135. Guarneri V, Chavez-MacGregor M, Hsu L, Symmans WF, Litton J, Mittendorf EA, Conte PF, Hortobagyi GN, Gonzalez-Angulo AM, Oncology DO, Hematology, Diseases AR, Hospital MU, Modena, Italy, Cancer Center UOTMDA, Houston, TX, Oncology DO, Hematology, Hospital U, Modena, Italy. Use of Ki-67 in residual disease following preoperative chemotherapy to predict of recurrence and death in breast cancer patients, 2010. e-Pub 2010.
136. Pusztai L, Moulder SL, Litton JK, Valero V, Ueno NT, Morrow PH, Dotter K, Mattair D, Strauss LC, Symmans WF, Cancer Center UOTMDA, Houston, TX, Squibb B, Wallingford, CT. Gene-signature-based patient selection for dasatinib therapy in metastatic breast cancer (MBC), 2010. e-Pub 2010.
137. Jackson M, Brandt A, Gutierrez-Barrera A, Meric-Bernstam F, Litton JK, Lu KH, Hortobagyi GN, Arun B, Cancer Center UOTMDA, Houston, TX. Effects of ethnicity on genotype-phenotype correlations in individuals with a BRCA1 or BRCA2 mutation, 2010. e-Pub 2010.
138. Chavez-MacGregor M, Hubbard R, Meric-Bernstam F, Shinde SS, Litton JK, Woodward WA, Valero V, Hortobagyi GN, Symmans WF, Gonzalez-Angulo AM, Cancer Center UOTMDA, Houston, TX, Pathology DO, Cancer Center UOTMDA, Houston, TX, at Urbana-Champaign UOI, Urbana, IL. Residual cancer burden (RCB) in breast cancer patients treated with taxane- and anthracycline-based neoadjuvant chemotherapy: The effect of race, 2010. e-Pub 2010.
139. Meric-Bernstam F, Gutierrez-Barrera A, Litton JK, Mellor-Crummey L, Ready K, Gonzalez-Angulo AM, Lu KH, Hortobagyi GN, Arun B, Cancer Center UOTMDA, Houston, TX. Mutation position in BRCA-associated breast cancers, 2010. e-Pub 2010.
140. Yu TK, Tereffe W, Bedrosian I, Eskambi SH, Strom EA, Litton JK, Gonzalez-Angulo AM, Buchholz TA, Hunt KK, Mittendorf EA, Center M, Houston, TX. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy, 2009. e-Pub 2009.
141. Litton JK, Ready K, Gutierrez-Barrera A. Earlier age of onset of BRCA mutation-related cancers in subsequent generations, 2009. e-Pub 2009.
142. Chavez-MacGregor M, Litton JK, Huiquin C, Meric-Bernstam F, Hudis CA, Wolff A, Valero V, Hortobagyi GN, Bondy ML, Gonzalez-Angulo AM, Texas UO, Center M, Houston, TX, Cancer Center MS, York N, NY, Cancer Center SKC, Baltimore, MD. Race and pathologic complete response (pCR) in breast cancer patients receiving anthracycline and taxane-based neoadjuvant chemotherapy, 2009. e-Pub 2009.
143. Silberfein EJ, Hunt KK, Broglio K, Shen J, Sahin A, Le-Petross H, Oh J, Litton JK, Hwang RF, Mittendorf EA, Center M, Houston, TX. Clinicopathologic factors associated with involved margins following breast conserving surgery for invasive lobular carcinoma (ILC), 2009. e-Pub 2009.
144. Ready, Gutierrez-Barrera AM, Litton JK, Meric-Bernstam F, Gonzalez-Angulo AM, Hortobagyi GN, Arun B. Racial differences in the use of contralateral prophylactic mastectomy among women undergoing BRCA1/BRCA2 genetic testing, 2009. e-Pub 2009.
145. Litton JK, Chen JQ, Warneke C, Zhang HZ, Berenstein N, Sahin A, Bondy ML, Hortobagyi GN, Murray JL, Radvany L. TRPS-1 in breast cancer, 2008. e-Pub 2008.
146. Arun B, Atchley D, Litton JK, Pusztai L, Valero V, Hortobagyi GN, Albarracin CT. Response to neoadjuvant chemotherapy in BRCA1- and BRCA2-related breast cancers, 2008. e-Pub 2008.
147. Rakkhit R, Broglio K, Peintinger F, Cardoso F, Hanrahan E, Litton J, Sahin A, Larsimont D, Meric-Bernstam F, Buchholz T, Valero V, Theriault R, Piccart M, Hortobagyi GN, Ravdin P, Gonzalez-Angulo AM. Significant increased recurrence rates among breast cancer patients with HER2-positiveT1abN0M0 tumors, 2008. e-Pub 2008.
148. Litton JK, Westin KN, Ready K, Sun CC, Peterson SK, Meric-Bernstam F, Bodurka DC, Lu KH, Hortobagyi GN, Arun BA. Perception of screening and risk-reduction surgeries in patients tested for a BRCA mutation, 2007. e-Pub 2007.
149. Litton JK, Gonzalez-Angulo AM, Warkene CL, Kau SW, Buzdar AU, Bondy M, Mahabir S, Hortobagyi GN, Brewster A. Body mass index and response to neoadjuvant chemotherapy, 2007. e-Pub 2007.

Book Chapters

1. Litton JK. Cancer and Pregnancy. In: Holland-Frei Cancer Medicine. Ninth. Wiley, 2017.
2. Litton JK, Theriault RL. Breast Cancer during Pregnancy and Subsequent Pregnancy in Breast Cancer Survivors. In: Diseases of the Breast. Fifth. Lippincott Williams & Wilkins, 855-63, 2014.
3. Litton JK, Hunt KK. Systemic Treatment Strategies for Early-Stage Breast Cancers. In: Evidence Based Medicine, 2011.
4. Litton JK, Theriault RL. Cancer and Pregnancy. In: Cancer Medicine. 8th. B.C. Decker, 830-837, 2010.
5. Litton JK, Hortobagyi GN. The Biology of the HER Family and HER2/neu Directed-Antibody Therapy. In: Macromolecular Anticancer Therapeutics. Humana, 437-464, 2010.
6. Litton JK. Cancer of the Breast - Special Topics - DCIS/LCIS/in Pregnancy. In: Clinical Care Options, 2010.
7. Litton JK, Theriault RL. Breast Cancer during Pregnancy and Subsequent Pregnancy in Breast Cancer Survivors. In: Diseases of the Breast. Fourth. Lippincott Williams & Wilkins, 808-816, 2008.
8. Litton JK, Theriault RL. Systemic Treatment during Pregnancy. In: Breast Surgery Office Management and Surgical Technique. Springer Verlag, 2008.
9. Ibrahim NK, Litton JK. Special Clinical Situations in Patients with Breast Cancer. In: Breast Cancer. Second, 2008.

Letters to the Editor

1. Litton JK, Lee JH, Arun BK. Reply to BRCA2-Associated Pancreatic Cancer and Current Screening Guidelines. Cancer 121: 3047, 2015.
2. Theriault RL, Litton JK. Reply to D. Crivellari et A. J Clin Oncol 32: 256-7, 2014.
3. Theriault RL, Litton JK. Pregnancy during or after breast cancer diagnosis: what do we know and what do we need to know?. J Clin Oncol 31: 2521-2, 2013.
4. Litton JK, Buzdar A, MacGregor MC, Gonzalez-Angulo A, Hortobagyi G. Tamoxifen therapy for patients with breast cancer. Lancet 381: 2077-8, 2013.
5. Litton JK, Gonzalez-Angulo AM. Evaluating breast cancer risk with genome-wide association studies: Is this approach patient ready?. J Clin Oncol 30: 4288-9, 2012.
6. Litton JK. Is age still the deciding factor?. The Oncologist 17: 744-6, 2012.
7. Litton JK, Brewster AM. Reply to Weight loss after breast cancer diagnosis may not improve prognosis. J Clin Oncol 27: 830-831, 2009.